

# CITATION REPORT

List of articles citing

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781

DOI: 10.1200/jco.2007.12.9593

Journal of Clinical Oncology, 2008, 26, 1086-92.

**Source:** <https://exaly.com/paper-pdf/44538845/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1164	Developments in treatment of esophageal/gastric cancer. <b>2008</b> , 9, 375-87		10
1163	Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. <b>2008</b> , 13, 474-8		11
1162	Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). <b>2008</b> , 8, 21		88
1161	Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. <b>2008</b> , 113, 1302-8		11
1160	Scientific surgery. <b>2008</b> , 95, 1191-1191		
1159	Impact of manual and automated interpretation of fused PET/CT data on esophageal target definitions in radiation planning. <b>2008</b> , 72, 1612-8		28
1158	Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. <b>2008</b> , 99, 1020-6		27
1157	Cancer of the Esophagus and Stomach. <b>2008</b> , 83, 712-722		9
1156	[Radiochemotherapy for oesophageal cancer: a locoregional failure history]. <b>2008</b> , 12, 640-8		5
1155	Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. <b>2008</b> , 8, 1953-64		3
1154	In Reply. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3100-3101	2.2	1
1153	Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. <b>2008</b> , 31, 360-1		3
1152	Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4551-6	2.2	98
1151	Nonmetastatic pancreatic cancer: many trials, little progress. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3100; author reply 3100-a-3101	2.2	6
1150	Treatment options for esophageal cancer. <b>2008</b> , 9, 3197-210		7
1149	Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5133-4; author reply 5134	2.2	7
1148	Cancer of the Esophagus and Stomach. <b>2008</b> , 83, 712-722		54

1147	Combined modality therapy of esophageal cancer. <b>2008</b> , 6, 851-60; quiz 861		14
1146	Systemic therapy for gastric cancer. 98-119		
1145	Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. <b>2009</b> , 15, 5983-91		87
1144	Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. <b>2009</b> , 101, 1298-306		56
1143	Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach?. <b>2009</b> , 5, 157-61		
1142	Clopidogrel plus aspirin in atrial fibrillation. <b>2009</b> , 361, 1312; author reply 1314-5		
1141	Case 19-2009: Carcinoma of the gastroesophageal junction. <b>2009</b> , 361, 1315; author reply 1315-6		
1140	Case records of the Massachusetts General Hospital. Case 19-2009. A 63-year-old woman with carcinoma of the gastroesophageal junction. <b>2009</b> , 360, 2656-64		3
1139	[Gastrointestinal oncology - therapy update 2008 / 2009]. <b>2009</b> , 47, 296-306		
1138	Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). <b>2009</b> , 20, 1522-1528		58
1137	Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. <b>2009</b> , 1, 145-65		5
1136	Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. <b>2009</b> , 115, 624-30		27
1135	Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. <b>2009</b> , 115, 3324-34		91
1134	Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. <b>2009</b> , 115, 4924-33		59
1133	The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. <b>2009</b> , 115, 5184-92		50
1132	Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. <i>Journal of Surgical Oncology</i> , <b>2009</b> , 100, 442-6	2.8	82
1131	A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma. <i>Journal of Surgical Oncology</i> , <b>2009</b> , 100, 435-41	2.8	24
1130	Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. <b>2009</b> , 17, 1109-16		16

1129	Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. <b>2009</b> , 74, 482-9		43
1128	Role of salvage esophagectomy after definitive chemoradiotherapy. <b>2009</b> , 57, 71-8		27
1127	[Combined preoperative radiochemotherapy in squamous cell carcinoma. The view of the medical oncologist]. <b>2009</b> , 80, 1006-10		
1126	Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. <i>World Journal of Surgery</i> , <b>2009</b> , 33, 2606-14	3.3	45
1125	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. <b>2009</b> , 100, 1725-30		16
1124	Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. <b>2009</b> , 24, 886-95		8
1123	Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. <i>Ecological Management and Restoration</i> , <b>2009</b> , 22, 127-32	3	13
1122	Chemoradiotherapy in gastrointestinal malignancies. <i>Clinical Oncology</i> , <b>2009</b> , 21, 543-56	2.8	21
1121	Neoadjuvant radiochemotherapy increases matrix metalloproteinase activity in healthy tissue in esophageal cancer patients. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 1384-9	3.1	8
1120	Tumors of the esophagus, gastroesophageal junction, and stomach. <b>2009</b> , 25, 61-75		11
1119	Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'. <b>2009</b> , 26, 185-94		2
1118	Multidisciplinary approach to esophageal and gastric cancer. <b>2009</b> , 89, 79-96, viii		27
1117	Emerging drugs for esophageal cancer. <b>2009</b> , 14, 329-39		13
1116	Evidence-based radiation oncology: oesophagus. <b>2009</b> , 92, 276-90		52
1115	Role of neoadjuvant therapy for esophageal adenocarcinoma. <b>2009</b> , 18, 533-46		11
1114	Preoperative therapy for esophageal cancer. <b>2009</b> , 38, 135-52, ix		12
1113	Future developments in esophageal cancer research. <b>2009</b> , 38, 183-8, x		3
1112	Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. <b>2009</b> , 32, 405-10		31

1111	Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. <b>2009</b> , 4, 1264-9		34
1110	Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. <b>2009</b> , 2009, 365-366		
1109	Impact of postoperative radiation after esophagectomy for esophageal cancer. <b>2010</b> , 5, 244-50		70
1108	Advancements in radiation techniques for gastric cancer. <b>2010</b> , 8, 428-35; quiz 436		3
1107	Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. <b>2010</b> , 23, 1331-7		10
1106	Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. <b>2010</b> , 5, 713-8		13
1105	A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. <b>2010</b> , 5, 229-35		45
1104	Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 98-108	3.1	9
1103	The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 791-803	3.1	47
1102	Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 1159-67	3.1	162
1101	Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 3187-94	3.1	35
1100	Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. <b>2010</b> , 186, 482-8		49
1099	Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. <b>2010</b> , 7, 1-6		3
1098	Carcinosarcoma of the esophagus treated with chemoradiotherapy: report of four cases. <b>2010</b> , 7, 119-125		13
1097	Multimodale Therapie beim Adenokarzinom des Ösophagus und des Ösophagogastralen Übergangs. <b>2010</b> , 16, 504-509		
1096	Neoadjuvante Therapie von Tumoren des oberen Gastrointestinaltrakts. <b>2010</b> , 5, 412-422		
1095	Management of esophageal cancer. <b>2010</b> , 47, 845-946		20
1094	Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature. <b>2010</b> , 210, 351-9		17

1093	Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. <b>2010</b> , 116, 1656-63		13
1092	Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. <b>2010</b> , 116, 4023-32		23
1091	Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. <b>2010</b> , 116, 4487-94		10
1090	Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. <b>2010</b> , 97, 719-25		25
1089	Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. <b>2010</b> , 97, 1482-96		110
1088	Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. <i>Journal of Surgical Oncology</i> , <b>2010</b> , 101, 299-304	2.8	22
1087	Advances in the surgical treatment of esophageal cancer. <i>Journal of Surgical Oncology</i> , <b>2010</b> , 101, 725-9	2.8	25
1086	Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials. <i>Journal of Surgical Oncology</i> , <b>2010</b> , 102, 932-6	2.8	14
1085	Preoperative radiochemotherapy for resectable localised oesophageal cancer: a controversial strategy. <b>2010</b> , 75, 235-42		7
1084	Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. <i>Ecological Management and Restoration</i> , <b>2010</b> , 23, 160-7	3	19
1083	The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic. <i>Ecological Management and Restoration</i> , <b>2010</b> , 23, 232-9	3	19
1082	Esophageal motion during radiotherapy: quantification and margin implications. <i>Ecological Management and Restoration</i> , <b>2010</b> , 23, 473-9	3	45
1081	Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e243-4; author reply e245	2.2	3
1080	Multimodality treatment for localized gastro-oesophageal cancer. <b>2010</b> , 21 Suppl 7, vii286-93		10
1079	Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?. <b>2010</b> , 21 Suppl 7, vii283-5		19
1078	The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. <b>2010</b> , 78, 316-22		18
1077	Perioperative management of esophageal cancer. <b>2010</b> , 7, 231-8		21
1076	An alternative postoperative pathway reduces length of hospitalisation following oesophagectomy. <b>2010</b> , 37, 807-13		53

1075	Das Plattenepithelkarzinom des Ösophagus Stellenwert der Chirurgie im therapeutischen Konzept. <b>2010</b> , 31, 288-294		
1074	The Association of Radiotherapy and Chemotherapy: Esophageal Cancer. <b>2010</b> , 5, 172-179		
1073	Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. <b>2010</b> , 6, 25-35		44
1072	[Squamous cell carcinoma of the oesophagus--impact of surgery within the therapeutic concept]. <b>2010</b> , 48, 560-6		
1071	Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?. <b>2010</b> , 71, 235-40		4
1070	Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. <b>2010</b> , 71, 686-93		108
1069	High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. <b>2010</b> , 8, 46		13
1068	Handbook of Evidence-Based Radiation Oncology. <b>2010</b> ,		32
1067	Outcomes of patients with esophageal cancer staged with [ <sup>18</sup> F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4714-21	2.2	107
1066	Esophagogastric cancer: targeted agents. <b>2010</b> , 36, 235-48		48
1065	Localized adenocarcinoma of the esophagogastric junction--is there a standard of care?. <b>2010</b> , 36, 400-9		7
1064	Randomized clinical trials in esophageal carcinoma. <b>2010</b> , 19, 59-80		15
1063	Adenocarcinoma of the Esophagogastric Junction. <b>2010</b> ,		3
1062	Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2010</b> , 21 Suppl 5, v46-9		94
1061	Oesophagogastric anastomosis complications in the Ivor Lewis operation. <b>2011</b> , 89, 175-181		
1060	Targeting the human EGFR family in esophagogastric cancer. <b>2011</b> , 8, 492-503		120
1059	Gastric adenocarcinoma surgery and adjuvant therapy. <b>2011</b> , 91, 1039-77		23
1058	Management of esophageal adenocarcinoma. <b>2011</b> , 148, e161-70		9

1057	Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. <b>2011</b> , 71, 541-55	11
1056	Esophageal Cancer. <b>2011</b> , 717-753	
1055	Principles of Anticancer Drug Development. <b>2011</b> ,	
1054	Induction Chemotherapy. <b>2011</b> ,	1
1053	Gastrointestinal Oncology. <b>2011</b> ,	
1052	Difficult Decisions in Thoracic Surgery. <b>2011</b> ,	1
1051	Traitement des adéocarcinomes de l'ophage. <b>2011</b> , 148, 184-195	
1050	Oesophagogastric junction adenocarcinoma: which therapeutic approach?. <b>2011</b> , 12, 296-305	138
1049	Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. <b>2011</b> , 12, 681-92	1181
1048	Is the predictive ability of positron emission tomography after neoadjuvant treatment for esophageal cancer ready for prime-time?. <b>2011</b> , 23, 87-8	
1047	Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). <b>2011</b> , 81, 684-90	243
1046	Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. <b>2011</b> , 81, 691-7	15
1045	Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. <b>2011</b> , 81, 1336-42	99
1044	Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 354-60	7.5 223
1043	Temporary Abdominal Coverage Using One or More Fish Visceral Retainers. <b>2011</b> , 77, 113-115	
1042	Remembering Semmelweis: Hand Hygiene and Its Importance on Today's Clinical Practice. <b>2011</b> , 77, 123-125	2
1041	Metastatic Adenocarcinoma Arising within a Diverticulum: Endoscopist's Nightmare. <b>2011</b> , 77, 109-110	2
1040	Perioperative Compartment Syndrome of the Hand. <b>2011</b> , 77, 116-118	2



1039	Partial Splenectomy Using a Vascular Stapler in a Patient with a Benign Splenic Cyst. <b>2011</b> , 77, 118-119	2
1038	Spontaneous Small Bowel Evisceration through a Skin Ulceration on a Massive Ventral Hernia. <b>2011</b> , 77, 120-122	1
1037	Pancreatic Metastases from Uterine Leiomyosarcoma with Vascular Involvement. <b>2011</b> , 77, 125-127	1
1036	Positron Emission Tomography and Carcinosarcoma of the Esophagus. <b>2011</b> , 77, 128-131	1
1035	An Unusual Cause of Iron Deficiency Anemia and Abdominal Pain in a Young Female. <b>2011</b> , 77, 127-128	1
1034	Idiopathic Spontaneous Intraperitoneal Hemorrhage: One Year Post Trauma Splenectomy. <b>2011</b> , 77, 110-111	1
1033	Solitary Fibrous Tumor of the Pelvis Treated with Preoperative Embolization and Pelvic Exenteration. <b>2011</b> , 77, 112-113	4
1032	Giant Sigmoid Diverticulum: A Rare Complication of a Common Disease. <b>2011</b> , 77, 115-116	
1031	Endoscopically-Assisted Tube Thoracostomy Placement in a Super-Morbidly Obese Patient with Penetrating Thoracoabdominal Trauma. <b>2011</b> , 77, 119-120	2
1030	Vaginal Evisceration Complicating Inguinal Hernia Repair. <b>2011</b> , 77, 122-123	
1029	Multifunctional Synthetic Poly(l-Glutamic Acid)Based Cancer Therapeutic and Imaging Agents. <b>2011</b> , 10, 7290.2011.00007	31
1028	Local effectiveness and complications of neoadjuvant therapy in esophageal squamous cell carcinoma: radiotherapy versus chemoradiotherapy. <b>2011</b> , 38, 227-34	8
1027	Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. <b>2011</b> , 2, 879-885	38
1026	TomoTherapy stereotactic body radiation therapy (SBRT) for the salvage treatment of locally recurrent esophageal adenocarcinoma following trimodality therapy: A case report. <b>2011</b> , 97, 406-410	6
1025	Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer. <b>2011</b> , 253, 279-84	38
1024	Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. <b>2011</b> , 34, 259-64	32
1023	Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. <b>2011</b> , 254, 274-80	95
1022	Multidisciplinary management of early and locally advanced esophageal cancer. <b>2011</b> , 45, 391-9	17

1021	Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. <b>2011</b> , 35, 647-55		42
1020	Esophageal carcinoma: matching patients with treatment methods. <b>2011</b> , 24, 28, 30-1		2
1019	Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. <b>2011</b> , 39, 1587-91		1
1018	Esophageal and esophagogastric junction cancers. <b>2011</b> , 9, 830-87		139
1017	Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2011</b> , 24, 330-6	3	4
1016	Barrett's esophagus: treatments of adenocarcinomas II. <b>2011</b> , 1232, 265-91		1
1015	Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer--do we need another randomised trial?. <i>Clinical Oncology</i> , <b>2011</b> , 23, 696-705	2.8	19
1014	High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. <b>2011</b> , 91, 1531-8		41
1013	Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival. <b>2011</b> , 91, 1509-15; discussion 1515-6		47
1012	Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. <b>2011</b> , 92, 491-6; discussion 496-8		65
1011	Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. <b>2011</b> , 92, 2034-40		66
1010	Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. <b>2011</b> , 92, 2020-7		34
1009	[Oesophagogastric anastomosis complications in the Ivor Lewis operation]. <b>2011</b> , 89, 175-81		5
1008	Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 551-8	3.1	28
1007	High expression of Y-box-binding protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3370-6	3.1	7
1006	Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3353-61	3.1	64
1005	Induction chemoradiotherapy followed by esophagectomy for advanced squamous cell carcinoma of the esophagus. <b>2011</b> , 8, 89-95		3
1004	Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. <b>2011</b> , 67, 621-7		3

1003	Gastric cancer. <b>2011</b> , 35, 97-127		9
1002	Prognostic implications of lymphadenectomy in esophageal cancer after neo-adjuvant therapy: a single center experience. <b>2011</b> , 15, 1769-76		13
1001	Multimodal treatment for resectable esophageal cancer. <b>2011</b> , 59, 461-6		14
1000	Targeted therapies for metastatic esophagogastric cancer. <b>2011</b> , 12, 46-60		12
999	The role of radiation in the perioperative treatment of esophagogastric cancer. <b>2011</b> , 12, 61-71		2
998	Update: modern approaches to the treatment of localized esophageal cancer. <i>Current Oncology Reports</i> , <b>2011</b> , 13, 157-67	6.3	5
997	Chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer patients: is it time for additional evidence?. <b>2011</b> , 9, 41		
996	Curative treatment of oesophageal carcinoma: current options and future developments. <b>2011</b> , 6, 55		32
995	Esophageal cancer--the five year survivors. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 179-83	2.8	96
994	The role of radiation therapy in the control of locoregional and metastatic cancer. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 627-38	2.8	6
993	Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. <b>2011</b> , 98, 768-83		132
992	Chemoradiation therapy in the management of gastrointestinal malignancies. <b>2011</b> , 7, 409-26		3
991	[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. <b>2011</b> , 49, 461-531		204
990	An expert opinion on esophageal cancer therapy. <b>2011</b> , 12, 225-39		13
989	Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh. <b>2011</b> , 34, 587-92		3
988	S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4555-60	2.2	42
987	Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. <b>2011</b> , 17, 3029-38		204
986	Chemoradiotherapy Experience In Locally Advanced Esophagial Cancer. <b>2011</b> ,		

985	Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer. <b>2011</b> , 81, 387-94		11
984	Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. <b>2011</b> , 106, 1048-54		74
983	Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients. <b>2011</b> , 105, 1864-73		31
982	Novel immunotherapeutic strategies of gastric cancer treatment. <b>2011</b> , 2011, 437348		30
981	The utility of proton beam therapy with concurrent chemotherapy for the treatment of esophageal cancers. <i>Cancers</i> , <b>2011</b> , 3, 4090-101	6.6	2
980	Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. <b>2012</b> , 23, 2827-2834		59
979	Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. <b>2012</b> , 23, 664-670		28
978	Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. <b>2012</b> , 106, 947-54		24
977	Locally advanced cancer of the esophagus, current treatment strategies, and future directions. <i>Frontiers in Oncology</i> , <b>2012</b> , 2, 52	5.3	3
976	Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. <b>2012</b> , 101, 26-31		18
975	Esophageal carcinoma advances in treatment results for locally advanced disease: review. <b>2012</b> , 23, 1095-1103	7.1	
974	Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. <b>2012</b> , 40, 2140-6		30
973	Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. <b>2012</b> , 35, 513-21		38
972	Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. <b>2012</b> , 28, 446-52		11
971	Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. <b>2012</b> , 9, 463-471		
970	Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. <b>2012</b> , 46, 337-45		2
969	CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. <b>2012</b> , 28, 465-72		74
968	Early evaluation of the apoptotic index ratio is useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell carcinoma. <b>2012</b> , 3, 287-292		1

967	Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. <b>2012</b> , 27, 940-6	24
966	Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. <b>2012</b> , 27, 1639-45	13
965	The CROSS trial: end of the debate on neoadjuvant therapy for esophageal cancer?. <b>2012</b> , 9, 607-609	
964	Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. <b>2012</b> , 57, 3226-33	32
963	Minimally invasive versus open oesophagectomy for oesophageal cancer. <b>2012</b> , 380, 883; author reply 885-6	4
962	Minimally invasive versus open oesophagectomy for oesophageal cancer [Authors' reply. <b>2012</b> , 380, 885-886	2
961	Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. <b>2013</b> , 100, 267-73	64
960	Impact of patient selection, disease progression, and adverse events on esophageal cancer outcomes after trimodality therapy. <b>2012</b> , 94, 1659-66	9
959	Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. <b>2012</b> , 94, 1862-8	32
958	Esophageal cancer dose escalation using a simultaneous integrated boost technique. <b>2012</b> , 82, 468-74	74
957	Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus. <b>2012</b> , 82, e513-9	44
956	Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. <b>2012</b> , 84, 471-7	45
955	Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. <b>2012</b> , 83, e231-9	15
954	Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. <b>2012</b> , 215, 643-51	45
953	Residual setup errors and dose variations with less-than-daily image guided patient setup in external beam radiotherapy for esophageal cancer. <b>2012</b> , 102, 309-14	21
952	The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. <b>2012</b> , 33, 1115-23	10
951	Evidence-based review of the management of cancers of the gastroesophageal junction. <b>2012</b> , 22, 109-21, vii-viii	4
950	Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. <b>2012</b> , 2, 41-5	10

949	Esophageal Carcinoma. <b>2012</b> , 493-534	1
948	. <b>2012</b> ,	2
947	Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma. <b>2012</b> , 203, 191-7	13
946	Diagnostic et traitement des adéocarcinomes de la jonction Éogastrique non méastatiques : quels standards actuels ?. <b>2012</b> , 149, 25-35	
945	Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?. <b>2012</b> , 10, 173	54
944	Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. <b>2012</b> , 10, 249	30
943	Definitive chemoradiotherapy for esophageal carcinoma. <b>2012</b> , 92, 1213-48	12
942	Management of advanced-stage operable esophageal cancer. <b>2012</b> , 92, 1179-97	11
941	What is the optimal interval between chemoradiation and esophagectomy?. <b>2012</b> , 24, 87-9	4
940	Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials. <b>2012</b> , 38, 599-604	74
939	A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3396-404	12
938	Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. <b>2012</b> , 75, 242-53	142
937	Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?. <b>2012</b> , 149, e23-33	23
936	Angiogenesis-related agents in esophageal cancer. <b>2012</b> , 12, 1335-45	8
935	Multi-modality therapy for cancer of the esophagus and GE junction. <b>2012</b> , 13, 390-402	7
934	The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. <b>2012</b> , 43, 612-8	13
933	Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophageal cancer. <b>2012</b> , 29, 1693-8	12
932	Long term disease-free survival in elderly patients following concurrent chemoradiotherapy for localized esophageal cancer. <b>2012</b> , 3, S92-S93	

931	Esophagectomy after chemoradiation: who and when to operate. <b>2012</b> , 24, 288-93		3
930	Tailoring esophageal cancer surgery. <b>2012</b> , 24, 275-87		4
929	Präoperative Radiochemotherapie beim Ösophaguskarzinom. <b>2012</b> , 18, 811-814		
928	A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. <b>2012</b> , 70, 683-90		24
927	Preoperative chemoradiotherapy for esophageal or junctional cancer. <b>2012</b> , 366, 2074-84		3133
926	Treatment of Esophageal and Hypopharyngeal Squamous Cell Carcinoma. <b>2012</b> ,		1
925	Local treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaT. <b>2012</b> , 2012, 421325		1
924	Prognostic Significance of Serum Neopterin in Patients with Esophageal Carcinoma. <b>2012</b> , 23, 22-26		2
923	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study. <b>2012</b> , 98, 451-457		4
922	Cisplatin and solid tumors: Still working, after all these years. <b>2012</b> , 2,		4
921	Targeted therapy for esophagogastric cancers: a review. <b>2012</b> , 5, 91-102		
920	Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 357-64	3.1	45
919	A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 68-74	3.1	811
918	Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. <b>2012</b> , 118, 2632-40		134
917	Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. <b>2012</b> , 118, 3268-76		16
916	Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. <b>2012</b> , 69, 1499-505		21
915	Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. <b>2012</b> , 17, 225-32		14
914	Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. <b>2012</b> , 31, 330-6		60

913	Does the timing of esophagectomy after chemoradiation affect outcome?. <b>2012</b> , 93, 207-12; discussion 212-3		64
912	Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. <b>2012</b> , 93, 1674-80		26
911	Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. <b>2012</b> , 143, 412-20		32
910	Discussion. <b>2012</b> , 143, 418-420		
909	Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma. <b>2012</b> , 103, 233-8		19
908	Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. <b>2012</b> , 103, 1617-24		25
907	Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma. <b>2012</b> , 27 Suppl 3, 88-94		6
906	Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. <i>Ecological Management and Restoration</i> , <b>2012</b> , 25, 130-6		16
905	Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. <i>Ecological Management and Restoration</i> , <b>2012</b> , 25, 638-44	3	49
904	Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision. <b>2012</b> , 118, 349-57		12
903	Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. <b>2012</b> , 130, 1706-13		70
902	Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. <b>2012</b> , 69, 655-63		17
901	Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. <i>Ecological Management and Restoration</i> , <b>2013</b> , 26, 487-95	3	5
900	Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. <b>2013</b> , 8, 116		35
899	Preoperative chemoradiotherapy for locally advanced gastric cancer. <b>2013</b> , 8, 6		15
898	Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. <b>2013</b> , 13, 75		7
897	Curative treatment of esophageal cancer; an evidenced based review. <b>2013</b> , 44, 375-84		19
896	High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma. <b>2013</b> , 30, 607		22



895 Adenokarzinome des Magens und gastroösophagealen Übergangs. **2013**, 19, 371-379

894 Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. **2013**, 7, 172-9

3

893 The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. **2013**, 95, 453-8

24

892 [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study]. **2013**, 17, 221-8

8

891 Management of gastroesophageal cancer: A perspective from Catalonia. **2013**, 15, 181-188

890 Adjuvant (postoperative) therapy for esophageal cancer. **2013**, 23, 525-33

10

889 Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer. **2013**, 23, 509-23

8

888 Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. **2013**, 6, 66

15

887 Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?. *Annals of Surgical Oncology*, **2013**, 20, 3009-14

3.1 24

886 Postchemoradiation resected locally advanced esophageal and gastroesophageal junction carcinoma: long-term outcome with or without intraoperative radiotherapy. *Annals of Surgical Oncology*, **2013**, 20, 1962-9

3.1 5

885 Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment. **2013**, 18, 977-82

6

884 Biomarkers in Oncology. **2013**,

1

883 Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. **2013**, 104, 1045-51

34

882 New therapeutic strategies for squamous cell cancer and adenocarcinoma. **2013**, 1300, 213-225

2

881 Overall survival and self-reported fatigue in patients with esophageal cancer. **2013**, 21, 511-9

19

880 Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. **2013**, 22, 511-24

13

879 Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients. **2013**, 12, 463-70

16

878 Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. **2013**, 96, 382-90

43

877	Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3149-58	7.5	102
876	Spatial-temporal [ <sup>18</sup> F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. <b>2013</b> , 85, 1375-82		118
875	Personalizing therapy for esophageal cancer patients. <b>2013</b> , 23, 471-8		5
874	Predictors of postoperative complications after trimodality therapy for esophageal cancer. <b>2013</b> , 86, 885-91		86
873	Oesophageal Chemoradiotherapy in the UK--current practice and future directions. <i>Clinical Oncology</i> , <b>2013</b> , 25, 368-77	2.8	22
872	Targeting therapy for esophageal cancer in patients aged 70 and over. <b>2013</b> , 4, 107-13		29
871	MIR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. <b>2013</b> , 104, 48-54		104
870	Emerging tyrosine kinase inhibitors for esophageal cancer. <b>2013</b> , 18, 219-30		9
869	Oesophageal carcinoma. <b>2013</b> , 381, 400-12		1669
868	Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. <b>2013</b> , CD008107		73
867	Chemotherapeutic options for gastroesophageal junction tumors. <b>2013</b> , 23, 24-30		9
866	Technical considerations in radiation therapy for gastroesophageal junction cancer. <b>2013</b> , 23, 51-9		4
865	The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. <b>2013</b> , 23, 60-73		14
864	Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: optimizing outcome. <b>2013</b> , 23, 38-50		12
863	Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 1660-7	3.1	4
862	Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3999-4007	3.1	17
861	Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2013</b> , 24 Suppl 6, vi51-6		162
860	The role of radiotherapy in the multimodal management of esophageal cancer. <b>2013</b> , 31, 30-7		16

859	Therapeutic and radiosensitizing effects of armillaridin on human esophageal cancer cells. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2013</b> , 2013, 459271	2.3	13
858	Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. <b>2013</b> , 258, 793-9; discussion 799-800		61
857	Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. <b>2013</b> , 24, 1262-6		73
856	Adjuvant treatment for gastric cancer: chemotherapy versus radiation. <b>2013</b> , 18, 1013-21		32
855	Capecitabine in the treatment of esophageal and gastric cancers. <b>2013</b> , 22, 1645-57		8
854	The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer. <b>2013</b> , 119, 1976-84		11
853	Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. <b>2013</b> , 119, 939-45		45
852	Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. <b>2013</b> , 104, 1455-60		127
851	Treatment options for esophageal squamous cell carcinoma. <b>2013</b> , 14, 1345-54		56
850	Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?. <b>2013</b> , 17, 460-6		15
849	Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. <b>2013</b> , 121, 2996-3004		152
848	Radiation therapy and esophageal cancer. <b>2013</b> , 20, 97-110		55
847	Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma. <b>2013</b> , 1, 773-779		13
846	Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. <b>2013</b> , 20, 89-96		25
845	Preoperative treatment of locally advanced esophageal carcinoma (Review). <b>2013</b> , 43, 1745-53		5
844	Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. <b>2013</b> , 8, 673-84		18
843	Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. <b>2013</b> , 30, 707-14		10
842	A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92. <b>2013</b> , 8, 1425-9		14

841 Locally Advanced Esophageal Cancer. **2013**,

840 New and emerging combination therapies for esophageal cancer. *Cancer Management and Research*, **2013**, 5, 133-46

3.6 25

839 Unanswered Questions in the Management of Gastroesophageal Junction Adenocarcinoma: An Overview from the Medical Oncologist's Perspective. **2013**, e155-e159

838 Esophageal Cancer: Treatment?. **2014**,

837 Multimodality management of esophageal cancer. **2014**, 76, 494-503

4

836 Randomized study of antiinflammatory and immune-modulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer. **2014**, 66, 1-5

40

835 A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus. **2014**, 9, 294

2

834 Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma. **2014**, 239, 529-41

15

833 Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. **2014**, 21, 125-33

9

832 Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. **2014**, 7, 534-540

3

831 Clinical stage T1-T2N0M0 oesophageal cancer: accuracy of clinical staging and predictive factors for lymph node metastasis. **2014**, 46, 274-9; discussion 279

22

830 Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. **2014**, 32, 497-506

2

829 Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. *Ecological Management and Restoration*, **2014**, 27, 662-9

3 21

828 Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). **2014**, 25, 1039-44

32

827 On endocytoscopy and posttherapy pathologic staging in esophageal cancers, and on evidence-based methodology. **2014**, 1325, 1-7

3

826 Patterns of recurrence after trimodality therapy for esophageal cancer. **2014**, 120, 2099-105

13

825 Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. *Ecological Management and Restoration*, **2014**, 27, 654-61

3 32

824 Esophageal carcinoma. **2014**, 371, 2499-509

790

823	Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. <i>Ecological Management and Restoration</i> , <b>2014</b> , 27, 235-41	3	7
822	Results of the FFCD 9901 trial in early-stage esophageal carcinoma: is it really about neoadjuvant therapy?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2398-400	2.2	8
821	WITHDRAWN: Multimodality treatment for locally advanced esophageal cancers. <b>2014</b> ,		
820	High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. <b>2014</b> , 44, 534-40		51
819	Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. <b>2014</b> , 9, 151		17
818	miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion. <b>2014</b> , 14, 138		27
817	Ranking candidate genes of esophageal squamous cell carcinomas based on differentially expressed genes and the topological properties of the co-expression network. <b>2014</b> , 19, 52		3
816	Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution. <b>2014</b> , 190, 1133-40		13
815	Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study. <b>2014</b> , 260, 764-70; discussion 770-1		57
814	Gastrointestinal cancer: nonliver proton therapy for gastrointestinal cancers. <b>2014</b> , 20, 378-86		5
813	What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. <b>2014</b> , 260, 1016-22		72
812	Thromboembolism during neoadjuvant therapy for gastrointestinal cancer. <b>2014</b> , 37, 627-34		2
811	Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 4375-82	3.1	6
810	Immunohistochemical analysis on potential new molecular targets for esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2014</b> , 27, 93-100	3	3
809	Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma. <b>2014</b> , 97, 1734-41		50
808	Collision tumor of esophagus: report of three cases. <b>2014</b> , 97, 1075-7		3
807	Invited commentary. <b>2014</b> , 97, 1741-2		
806	Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1065-75	7.5	21

805	Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival. <i>World Journal of Surgery</i> , <b>2014</b> , 38, 106-13	3.3	21
804	A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. <b>2014</b> , 73, 665-71		21
803	Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 575-82	3.1	23
802	Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis. <b>2014</b> , 11, 173-181		7
801	Clinical significance of muscle layer interruption in T3 esophageal cancer. <b>2014</b> , 11, 117-125		
800	[Combined modality treatment of oesophageal cancer]. <b>2014</b> , 55, 7-8, 10-4		2
799	Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. <i>Ecological Management and Restoration</i> , <b>2014</b> , 27, 355-9	3	22
798	The current status of neoadjuvant therapy for esophageal cancer. <b>2014</b> , 26, 102-9		8
797	Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. <b>2014</b> , 101, 321-38		147
796	Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 109, 287-93	2.8	16
795	Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2950-7	7.5	27
794	The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. <b>2014</b> , 98, 1880-5		45
793	Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 385-91	2.2	283
792	Difficult Decisions in Thoracic Surgery. <b>2014</b> ,		3
791	Esophageal Diseases. <b>2014</b> ,		
790	Perioperative therapy for esophageal cancer. <b>2014</b> , 62, 531-40		11
789	Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. <i>World Journal of Surgery</i> , <b>2014</b> , 38, 2046-51	3.3	20
788	Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. <b>2014</b> , 9, 45		13

787	Role of chemoradiotherapy in oesophageal cancer -- adjuvant and neoadjuvant therapy. <i>Clinical Oncology</i> , <b>2014</b> , 26, 522-32	2.8	13
786	Combination chemoradiation therapy: the whole is more than the sum of the parts. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 367-9	2.2	17
785	Therapeutic approaches to gastroesophageal junction adenocarcinomas. <b>2014</b> , 1325, 197-210		2
784	Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. <b>2014</b> , 88, 195-203		67
783	False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. <b>2014</b> , 4, 368-71		2
782	Extracorporeal membrane oxygenation support after Ivor-Lewis esophagectomy for esophageal adenocarcinoma. <b>2014</b> , 97, 1073-5		2
781	Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. <b>2014</b> , 12, 1139-44		13
780	Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward. <b>2014</b> , 1, 99-104		4
779	Mesenchymal phenotype after chemotherapy is associated with chemoresistance and poor clinical outcome in esophageal cancer. <b>2014</b> , 31, 589-96		17
778	Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction. <b>2015</b> , 349, 472-6		14
777	The Prognostic Impact of Preoperative and Postoperative Chemoradiation in Clinical Stage II and III Esophageal Squamous Cell Carcinomas: A Population Based Study in Taiwan. <b>2015</b> , 94, e1002		10
776	[Not Available]. <b>2015</b> , 53, 1288-347		34
775	Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. <b>2015</b> , 31, 347-53		6
774	Impact of number of [(18)F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. <b>2016</b> , 103, 97-104		15
773	Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. <i>Scientific Reports</i> , <b>2015</b> , 5, 17336	4.9	8
772	Combined modality therapy in locally advanced esophageal cancer. <b>2015</b> , 221-230		
771	Radiation therapy for locally advanced esophageal cancer. <b>2015</b> , 237-250		
770	Proton Therapy: A New Dawn for Gastrointestinal Cancer Treatment. <b>2015</b> , 637-646		



769	Adjuvant therapy for resected pancreatic cancer. <b>2015</b> ,		1
768	Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. <b>2015</b> , 94, e1102		19
767	Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma. <b>2015</b> , 10, 181-8		17
766	The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 112, 597-602	2.8	26
765	Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols. <b>2015</b> , 15, 813		8
764	A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer. <b>2015</b> , 10, 212		2
763	Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 112, 629-33	2.8	1
762	Multimodality approaches for the curative treatment of esophageal cancer. <b>2015</b> , 13, 229-38		38
761	Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma. <i>Ecological Management and Restoration</i> , <b>2015</b> , 28, 380-5	3	4
760	Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. <i>Ecological Management and Restoration</i> , <b>2015</b> , 28, 612-8	3	16
759	Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy. <b>2015</b> , 38, 564-9		17
758	Patterns of nodal metastases on 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma are useful to guide treatment planning of radiotherapy. <b>2015</b> , 40, 384-9		5
757	Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2015</b> , 28, 619-25	3	4
756	Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 112, 60-5	2.8	18
755	A review of the impact of preoperative chemoradiotherapy on outcome and postoperative complications in esophageal cancer patients. <b>2015</b> , 38, 415-21		15
754	Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2015</b> , 28, 788-96	3	15
753	Circulating Tumor Cell Analyses in Patients With Esophageal Squamous Cell Carcinoma Using Epithelial Marker-Dependent and -Independent Approaches. <b>2015</b> , 94, e1565		26
752	Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. <b>2015</b> , 262, 280-5		32



751	. <b>2015</b> ,	1
750	Casticin treatment inhibits squamous cell carcinoma cell proliferation and arrests cell cycle in S phase. <b>2015</b> , 11, 206	1
749	External beam radiotherapy synergizes $\text{Fe}$ -liposome against human esophageal cancer xenograft and modulates $\text{Fe}$ -liposome pharmacokinetics. <b>2015</b> , 10, 3641-9	7
748	An Unusual Course of Metastatic Gastroesophageal Cancer. <b>2015</b> , 2015, 941508	
747	Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. <b>2015</b> , 10, 509-17	28
746	Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer. <b>2015</b> , 27, 351-7	32
745	Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage. <b>2015</b> , 19, 1201-7	5
744	Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. <b>2015</b> , 92, 911-20	74
743	Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. <b>2015</b> , 15, 322	21
742	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <b>2015</b> , 20, 1132-9	69
741	Aortic pseudoaneurysm formation following concurrent chemoradiotherapy and metallic stent insertion in a patient with esophageal cancer. <b>2015</b> , 94, e862	5
740	Esophageal Cancer: Molecular Mechanisms, Diagnosis and Treatment. <b>2015</b> , 201-228	1
739	Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. <b>2015</b> , 16, e23-31	47
738	Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. <b>2015</b> , 99, 270-6	40
737	Current status of management of malignant disease: current management of esophageal cancer. <b>2015</b> , 19, 964-72	49
736	Emerging mAbs for the treatment of esophagogastric cancer. <b>2015</b> , 20, 63-74	1
735	Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?. <b>2015</b> , 19, 587-93	5
734	Brain Metastases from Esophageal Cancer in the Presence of HER-2 Overexpression. <b>2015</b> , 147-152	

733	The implications and mechanisms of the extra-nuclear nucleolin in the esophageal squamous cell carcinomas. <b>2015</b> , 32, 45		11
732	Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. <b>2015</b> , 41, 282-94		27
731	Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomy. <b>2015</b> , 48, 455-60; discussion 460-1		13
730	ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 453-63	4.9	16
729	Locally advanced gastroesophageal junction tumor: a treatment dilemma. <b>2015</b> , 20, 134-42		4
728	Prognostic significance of lymph node ratio in esophageal cancer. <b>2015</b> , 36, 2335-41		17
727	A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. <b>2015</b> , 149, 538-47		14
726	Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma. <b>2015</b> , 45, 169-75		4
725	[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients]. <b>2015</b> , 19, 322-30		2
724	Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3866-73	2.2	119
723	Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. <b>2015</b> , 113, 603-10		21
722	Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. <b>2015</b> , 63, 549-56		10
721	Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. <b>2015</b> , 115, 9-15		8
720	Anticancer effects of crocetin in human esophageal squamous cell carcinoma KYSE-150 cells. <b>2015</b> , 9, 1254-1260		29
719	The crucial role of SRPK1 in TGF- $\beta$ -induced proliferation and apoptosis in the esophageal squamous cell carcinomas. <b>2015</b> , 32, 209		16
718	Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. <b>2015</b> , 16, 35		11
717	Comparative effectiveness in esophagogastric cancer. <b>2015</b> , 164, 121-42		1
716	Radiation Therapy. <b>2015</b> , 227-249		

715	Controversies in the treatment of local and locally advanced gastric and esophageal cancers. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1754-9	2.2	60
714	Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer. <b>2015</b> , 99, 1887-93		25
713	Chemoradiation in oesophageal cancer. <b>2015</b> , 29, 193-209		12
712	Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy. <b>2015</b> , 46, 131-7		18
711	Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy. <b>2015</b> , 10, 59		21
710	Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 1020-5	3.1	7
709	Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. <b>2015</b> , 36, 7987-96		25
708	Intensity-Modulated Radiation Therapy. <b>2015</b> ,		3
707	Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. <b>2015</b> , 149, 302-17.e1		231
706	Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. <b>2015</b> , 10, 518-26		2
705	Principles of Radiation Therapy. <b>2015</b> , 157-172		
704	Serum Transforming Growth Factor- $\beta$ Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. <b>2015</b> , 93, 1023-31		2
703	Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2015</b> , 28, 358-64	3	29
702	[Are extensive fields useful for radiotherapy of esophageal cancer?]. <b>2015</b> , 19, 313-21		
701	Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. <b>2015</b> , 45, 1023-8		23
700	Esophageal Cancer. <b>2015</b> ,		1
699	18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2545-52	7.5	34
698	Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3854-7	2.2	7

697	Esophageal Squamous Cell Carcinoma. <b>2015</b> ,	2
696	International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. <b>2015</b> , 18, 550-63	58
695	Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer. <b>2015</b> , 20, 531-7	10
694	Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?. <b>2015</b> , 18, 1-10	15
693	Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting. <b>2016</b> , 102, 459-471	8
692	C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome. <b>2016</b> , 7, 587-94	15
691	Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. <b>2016</b> , 7, 403-10	15
690	EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. <b>2016</b> , 7, 838-847	3
689	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. <b>2016</b> , 7, 828-837	5
688	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. <b>2016</b> , 7, 644-64	44
687	Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis. <b>2016</b> , 129, 2974-2982	4
686	Esophageal cancer: comparative effectiveness of treatment options. <b>2016</b> , 1	1
685	Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. <i>Frontiers in Oncology</i> , <b>2016</b> , 6, 72	5.3 37
684	Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. <b>2016</b> , 7, 50624-50634	6
683	Advances in Radiotherapy Management of Esophageal Cancer. <b>2016</b> , 5,	24
682	Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. <b>2016</b> , 16, 468	10
681	Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. <b>2016</b> , 22, 275-283	31
680	Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. <b>2016</b> , 39, 448-52	4

679	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. <b>2016</b> , 122, 2083-90		23
678	Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 113, 390-6	2.8	21
677	Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies. <i>Ecological Management and Restoration</i> , <b>2016</b> , 29, 1107-1114	3	17
676	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. <b>2016</b> ,		2
675	MMP1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma. <b>2016</b> , 377, 97-104		71
674	Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?. <b>2016</b> , 102, 433-8		23
673	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. <b>2016</b> , 101, 1075-80; Discussion 1080-1		14
672	Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. <b>2016</b> , 42, 1183-90		14
671	Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience. <b>2016</b> , 47, 313-7		1
670	Cervical esophageal cancer: a gap in cancer knowledge. <b>2016</b> , 27, 1664-74		51
669	Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management. <b>2016</b> , 64, 386-94		11
668	Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy. <b>2016</b> , 89, 20160350		11
667	Potentially Curable Cancers of the Esophagus and Stomach. <b>2016</b> , 91, 1307-18		1
666	The Role of Peri-Operative Therapy in Esophageal and Gastric Cancers. <b>2016</b> , 87-105		
665	Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review. <b>2016</b> , 107, 128-137		15
664	Cancer of the Esophagus. <b>2016</b> , 843-864.e7		
663	Gastric/GE Junction Cancer. <b>2016</b> , 906-933.e5		2
662	Overview. <b>2016</b> , 788-797.e4		

661	Stage-directed individualized therapy in esophageal cancer. <b>2016</b> , 1381, 50-65		11
660	Impact of Neoadjuvant Chemoradiation on Short-Term Outcomes for Esophageal Squamous Cell Carcinoma Patients: A Meta-analysis. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 3632-3640	3.1	13
659	Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 114, 296-303	2.8	5
658	Efficacy and Safety of Induction Chemotherapy in Esophageal Cancer with Airway Involvement. <b>2016</b> , 47, 294-304		4
657	Esophageal cancer: The latest on chemoprevention and state of the art therapies. <b>2016</b> , 113, 236-244		22
656	Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives. <b>2016</b> , 25, 355-363		9
655	Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients. <b>2016</b> , 11, 2227-2237		34
654	Transhiatal Esophagectomy for Esophageal Cancer. <b>2016</b> , 26, 752-756		2
653	PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma. <b>2016</b> , 37, 14217-14224		16
652	Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. <b>2016</b> , 96, 985-993		48
651	Principles of Chemotherapy. <b>2016</b> , 171-185.e2		
650	Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. <b>2016</b> , 30, 551-63		10
649	No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. <b>2016</b> , 223, 784-792.e1		13
648	The Role of Induction Therapy for Esophageal Cancer. <b>2016</b> , 26, 295-304		1
647	RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 570-580	3.2	9
646	Comments on Radical Esophagectomy after Neoadjuvant Chemoradiation: Single Institutional Experience from Tertiary Cancer Centre in India. <b>2016</b> , 7, 373-374		1
645	Feeding Challenges in Patients with Esophageal and Gastroesophageal Cancers. <b>2016</b> , 2, 166-77		24
644	Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy. <b>2016</b> , 37, 1282-1289		5

643	A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. <b>2016</b> , 16, 644		19
642	Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation. <b>2016</b> , 11, 156		7
641	Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma. <b>2016</b> , 102, 1132-9		27
640	Induction Chemotherapy. <b>2016</b> ,		3
639	High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort. <b>2016</b> , 192, 458-66		9
638	Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions. <b>2016</b> , 26, 307-19		0
637	Cumulative scores based on plasma D-dimer and serum albumin levels predict survival in esophageal squamous cell carcinoma patients treated with transthoracic esophagectomy. <b>2016</b> , 35, 11		11
636	Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy. <b>2016</b> , 90, 97-102		14
635	Interaction of Chemotherapy and Radiation. <b>2016</b> , 63-79.e4		3
634	Treatment outcomes of cervical esophageal cancer patients. <b>2016</b> , 13, 323-329		1
633	Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy. <i>Ecological Management and Restoration</i> , <b>2016</b> , 29, 614-20	3	19
632	Optimal surgical approach for esophageal cancer in the era of minimally invasive esophagectomy and neoadjuvant therapy. <i>Ecological Management and Restoration</i> , <b>2016</b> , 29, 773-779	3	4
631	Endoscopic steroid injection reduced frequency of repeat dilation in patients with anastomotic stenosis after esophagectomy. <b>2016</b> , 13, 62-67		4
630	Challenges in oral drug delivery in patients with esophageal dysphagia. <b>2016</b> , 13, 645-58		12
629	A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. <b>2016</b> , 27, 660-7		200
628	Advances in the Management of Gastric and Gastroesophageal Cancers. <i>Current Oncology Reports</i> , <b>2016</b> , 18, 13	6.3	6
627	Patterns of Regional Lymph Node Recurrence After Radical Surgery for Thoracic Esophageal Squamous Cell Carcinoma. <b>2016</b> , 101, 551-7		16
626	Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma. <b>2016</b> , 101, 1123-30		36



625	Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes. <b>2016</b> , 101, 2148-54		21
624	Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma. <b>2016</b> , 18, 1106-1113		5
623	Different accuracy of endosonographic tumor staging after neoadjuvant chemotherapy and chemoradiotherapy in esophageal cancer. <b>2016</b> , 30, 2922-8		10
622	Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. <b>2016</b> , 94, 738-46		13
621	Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. <b>2016</b> , 55, 303-8		8
620	Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. <i>European Journal of Cancer</i> , <b>2016</b> , 52, 1-9	7.5	91
619	The upregulation of miRNA-146a inhibited biological behaviors of ESCC through inhibition of IRS2. <b>2016</b> , 37, 4641-7		24
618	Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 273-81	3.1	17
617	Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <b>2016</b> , 46, 261-7		9
616	Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. <b>2017</b> , 40, 393-398		4
615	Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer. <b>2017</b> , 265, 356-362		23
614	eComment. Neoadjuvant chemoradiotherapy: where is the real controversy?. <b>2017</b> , 24, 119-120		1
613	Surgically treated oesophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes. <i>European Journal of Cancer</i> , <b>2017</b> , 75, 179-189	7.5	4
612	Management of Gastroesophageal Junction Tumors. <b>2017</b> , 97, 265-275		7
611	Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer. <b>2017</b> , 13, 1807-1810		4
610	Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer. <b>2017</b> , 103, 1101-1108		17
609	Adjuvant therapy for resected pancreatic cancer. <b>2017</b> ,		0
608	Radiation Therapy for Locally Advanced Esophageal Cancer. <b>2017</b> , 26, 257-276		13



607	Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. <b>2017</b> , 98, 811-819		29
606	Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. <b>2017</b> , 26, 241-256		1
605	Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. <i>European Journal of Cancer</i> , <b>2017</b> , 76, 8-16	7.5	19
604	Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. <b>2017</b> , 34, 40		5
603	FDG PET using SUV for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy. <b>2017</b> , 17, 1		24
602	Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus. <b>2017</b> , 2, 325-332		7
601	Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2282-2290	3.1	24
600	Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?. <b>2017</b> , 52, 543-551		14
599	Carcinoma of the Esophagus. <b>2017</b> , 385-396		
598	Role of Adjuvant Treatment in Esophageal Cancer With Incidental Pathologic Node Positivity. <b>2017</b> , 104, 267-274		5
597	Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. <b>2017</b> , 12, 1152-1160		43
596	Minimally Invasive Esophagectomy for Adenocarcinomas of the Gastroesophageal Junction and Distal Esophagus: Notes on Technique. <b>2017</b> , 27, 162-169		1
595	Phase II study of preoperative concurrent chemoradiotherapy with oxaliplatin for locally advanced esophageal cancer. <b>2017</b> , 80, 401-407		3
594	Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. <b>2017</b> , 26, 405-429		5
593	Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. <b>2017</b> , 5, 549-557		
592	Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). <b>2017</b> , 43, 1550-1558		10
591	Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes. <b>2017</b> , 2, 308-315		
590	A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2017</b> , 30, 1-8	3	8

589	Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. <b>2017</b> , 216, 65-72		15
588	Current and future treatment options for esophageal cancer in the elderly. <b>2017</b> , 18, 1001-1010		69
587	Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma. <b>2017</b> , 123, 3904-3915		39
586	TCN, an AKT inhibitor, exhibits potent antitumor activity and enhances radiosensitivity in hypoxic esophageal squamous cell carcinoma and. <b>2017</b> , 13, 949-954		5
585	The Role of Radiotherapy in Localized Esophageal and Gastric Cancer. <b>2017</b> , 31, 453-468		16
584	Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. <b>2017</b> , 10, 649-660		11
583	Multidisciplinary Approach to the Management of Esophageal Malignancies. <i>World Journal of Surgery</i> , <b>2017</b> , 41, 1726-1733	3-3	4
582	Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. <b>2017</b> , 265, 481-491		109
581	Oesophageal cancer: Which treatment is the easiest to swallow? A review of combined modality treatments for resectable carcinomas. <b>2017</b> , 113, 135-150		7
580	Handbook of Image-Guided Brachytherapy. <b>2017</b> ,		2
579	High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 219-228	3-2	8
578	Esophageal Cancer: New Insights into a Heterogenous Disease. <b>2017</b> , 95, 253-261		16
577	Survival benefit of surgery to patients with esophageal squamous cell carcinoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 46139	4-9	20
576	Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. <i>World Journal of Surgery</i> , <b>2017</b> , 41, 1719-1725	3-3	3
575	Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer. <b>2017</b> , 23, 657-663		1
574	Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer. <b>2017</b> , 92, 101-108		22
573	Endoscopic and Imaging Predictors of Complete Pathologic Response After Chemoradiation for Esophageal Cancer. <b>2017</b> , 19, 57		6
572	An Update on Randomized Clinical Trials in Gastric Cancer. <b>2017</b> , 26, 621-645		

571 Cáncer de esófago. **2017**, 12, 1889-1903

570 Oesophageal cancer. **2017**, 3, 17048

367

569 Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. **2017**, 43, 1572-1580

19

568 Do male esophageal cancer patients have impaired sexual function after esophagectomy? A self-reported outcomes study. **2017**, 26, 3331-3341

1

567 Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer. *Ecological Management and Restoration*, **2017**, 30, 1-8

3

11

566 Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. **2017**, 18, 1249-1260

134

565 Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers. **2017**, 34, 157

2

564 Efficacy and safety of endoscopic submucosal dissection for superficial cancer of the cervical esophagus. **2017**, 5, E736-E741

12

563 Multimodale Therapie des Ösophaguskarzinoms. **2017**, 23, 771-788

2

562 Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. *European Journal of Cancer*, **2017**, 81, 183-190

7.5

111

561 Oncologic Quality Indicators in Thoracic Surgery. **2017**, 27, 227-244

8

560 CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cTNM) (NCT02201503). **2017**, 17, 150

17

559 ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). **2017**, 17, 401

88

558 Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. **2017**, 12, 97

14

557 Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. **2017**, 12, 375-382

43

556 Final Results of NRG Oncology RTOG 0246: An 'Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. **2017**, 12, 368-374

45

555 Utility of F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. **2017**, 12, 121-128

16

554 Utilization of surgical treatment for local and locoregional esophageal cancer: Analysis of the National Cancer Data Base. **2017**, 123, 410-419

17

553	Esophageal cancer's 100 most influential manuscripts: a bibliometric analysis. <i>Ecological Management and Restoration</i> , <b>2017</b> , 30, 1-8	3	11
552	Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer. <b>2018</b> , 15, 2017-2023		10
551	Prognostic relevance of serial endoscopic ultrasound after chemoradiation in esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2017</b> , 30, 1-8	3	2
550	Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy. <b>2018</b> , 15, 1200-1210		1
549	Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2017</b> , 30, 1-9	3	13
548	Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation. <b>2017</b> , 6, 144-151		19
547	Predictive significance of HMGS2 for prognosis in resected Chinese esophageal squamous cell carcinoma patients. <b>2017</b> , 10, 2553-2560		12
546	Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre. <b>2017</b> , 12, e0184737		3
545	DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer. <b>2017</b> , 12, 128		10
544	Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus. <b>2017</b> , 12, 182		11
543	Traditional and cumulative meta-analysis: Chemoradiotherapy followed by surgery versus surgery alone for resectable esophageal carcinoma. <b>2018</b> , 8, 342-351		6
542	A nomogram based on phosphorylated AKT1 for predicting locoregional recurrence in patients with oesophageal squamous cell carcinoma. <b>2017</b> , 8, 3755-3763		2
541	Does neoadjuvant chemoradiotherapy increase survival in patients with resectable oesophageal cancer?. <b>2017</b> , 24, 115-120		8
540	Cancer of the esophagus and esophagogastric junction: an 8 edition staging primer. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, E282-E284	2.6	17
539	Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract. <b>2017</b> , 118-129		
538	Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 318-326	2.6	4
537	Salvage esophagectomy: safe therapeutic strategy?. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, S799-S808	2.6	11
536	Deciding on the neoadjuvant approach for esophageal adenocarcinomas. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 1818-1821	2.6	

535	Esophageal cancer developed in a radiated field: can we reduce the risk of a poor prognosis cancer?. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 1767-1771	2.6	7
534	Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, S697-S704	2.6	20
533	Adjuvant radiotherapy for positive lymph nodes of oesophageal squamous cell carcinoma: Can it earn promising benefits at long-term follow-up?. <b>2018</b> , 22, 140-147		2
532	Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. <b>2018</b> , 14, 125-133		3
531	Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma. <b>2018</b> , 34, 281-289		2
530	Totally minimally invasive esophagectomy after neoadjuvant chemoradiotherapy: Long-term oncologic outcomes. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 651-658	2.8	8
529	Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. <b>2018</b> , 143, 430-437		38
528	Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. <b>2018</b> , 155, 2221-2230.e1		17
527	Laser-assisted delivery of synergistic combination chemotherapy in in vivo skin. <b>2018</b> , 275, 242-253		20
526	Esophageal Cancer. <b>2018</b> , 33-53		
525	Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. <b>2018</b> , 194, 435-443		5
524	Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. <i>Ecological Management and Restoration</i> , <b>2018</b> , 31,	3	16
523	Mid/Distal Esophageal Cancer and Gastroesophageal Junction Cancer (Siewert Type I and II). <b>2018</b> , 21-50		
522	Gastric Cancer (Siewert Type III). <b>2018</b> , 53-91		
521	Radiotherapy for Esophageal Adenocarcinoma. <b>2018</b> , 1756, 7-17		1
520	Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. <b>2018</b> , 28, 114-124		5
519	Tumour motion of oesophageal squamous cell carcinoma evaluated by cine MRI: associated with tumour location. <b>2018</b> , 73, 676.e1-676.e7		4
518	Customization of therapy for gastroesophageal adenocarcinoma patients. <b>2018</b> , 4, 8-17		1

517	Induction therapy for locally advanced distal esophageal adenocarcinoma: Is radiation Always necessary?. <b>2018</b> , 155, 2697-2707		2
516	Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy. <i>Surgery</i> , <b>2018</b> ,	3.6	12
515	Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival. <b>2018</b> , 57, 1192-1200 <sup>11</sup>		
514	Antitumoral potential, antioxidant activity and carotenoid content of two Southern Italy tomato cultivars extracts: San Marzano and Corbarino. <b>2018</b> , 233, 1266-1277		20
513	Study of neoadjuvant chemoradiotherapy with combined S-1 and low-dose cisplatin for patients with clinical stage II/III esophageal cancer. <b>2018</b> , 41, 148-154		
512	Radiomics in Oncological PET/CT: Clinical Applications. <b>2018</b> , 52, 170-189		53
511	Nutritional optimization during neoadjuvant therapy prior to surgical resection of esophageal cancer-a narrative review. <i>Ecological Management and Restoration</i> , <b>2018</b> , 31, 1-11	3	28
510	Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer. <b>2018</b> , 36, 23-29		1
509	Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis. <i>Ecological Management and Restoration</i> , <b>2018</b> , 31, 1-9	3	7
508	Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. <i>World Journal of Surgery</i> , <b>2018</b> , 42, 1496-1505	3.3	17
507	Perioperative chemotherapy vs. neoadjuvant chemoradiation in 'gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. <b>2018</b> , 194, 125-135		11
506	Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. <b>2018</b> , 4, 31-38		41
505	The Significance of SCC and CEA mRNA in the Pleural Cavity After Lymphadenectomy in Esophageal Cancer Patients who Underwent Preoperative Treatment. <i>World Journal of Surgery</i> , <b>2018</b> , 42, 749-757	3.3	7
504	Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. <i>Journal of Surgical Oncology</i> , <b>2018</b> , 117, 150-159	2.8	11
503	Optimal Therapy in Locally Advanced Esophageal Cancer: a National Cancer Database Analysis. <b>2018</b> , 22, 187-193		3
502	Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer. <b>2018</b> , 9, 40-46		7
501	Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. <b>2018</b> , 154, 437-451		51
500	Novel endoscopic categorization for prediction of chemoradiotherapy response in locally advanced esophageal cancer. <b>2018</b> , 33, 1213-1219		

499	Preoperative enteral access is not necessary prior to multimodality treatment of esophageal cancer. <i>Surgery</i> , <b>2018</b> , 163, 770-776	3.6	13
498	Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study. <b>2018</b> , 124, 1122-1131		9
497	Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma. <b>2018</b> , 94, 47-54		8
496	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <b>2018</b> , 13, 69-78		
495	Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2796-2803	2.2	267
494	Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer. <b>2018</b> , 9, 73-79		9
493	Anastomotic leak and neoadjuvant chemoradiotherapy in esophageal cancer. <b>2018</b> , 9, 894-902		12
492	Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. <b>2018</b> , 9, 80-89		23
491	Editorial comments for neoadjuvant chemo-radiotherapy in the treatment of locally advanced squamous cell esophageal cancer. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, 5979-5981	2.6	1
490	Combining immunotherapy with radiation therapy in thoracic oncology. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, S2492-S2507	2.6	10
489	Correlation between Bax gene polymorphisms and esophagus cancer. <b>2018</b> , 16, 7097-7101		3
488	High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. <b>2019</b> , 17, 1626-1634		8
487	Underutilization of the CROSS Regimen Among US Radiation Oncologists: A National Survey of Practice Patterns. <b>2018</b> , 38, 6375-6379		1
486	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. <b>2018</b> , 36-37, 45-52		11
485	Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis. <i>Scientific Reports</i> , <b>2018</b> , 8, 15073	4.9	5
484	Neoadjuvant chemoradiotherapy for resectable oesophageal cancer. <b>2018</b> , 36-37, 37-44		10
483	Recurrence and prognostic model for identifying patients at risk for esophageal cancer after surgery. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 6109-6120	3.6	3
482	Neoadjuvant therapy for esophageal cancer: Who, when, and what?. <b>2018</b> , 124, 4276-4278		4



481	The management of mid & proximal oesophageal squamous cell carcinoma. <b>2018</b> , 36-37, 85-90		7
480	A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. <b>2018</b> , 132, 161-168		6
479	Aspirin acts in esophageal cancer: a brief review. <i>Journal of Thoracic Disease</i> , <b>2018</b> , 10, 2490-2497	2.6	6
478	Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus. <b>2018</b> , 38, 5239-5245		5
477	Survival Impact of Delaying Postoperative Radiotherapy in Patients with Esophageal Cancer. <b>2018</b> , 11, 1358-1363		5
476	Endoscopic Balloon Dilation Followed By Intralesional Steroid Injection for Anastomotic Strictures After Esophagectomy: A Randomized Controlled Trial. <b>2018</b> , 113, 1468-1474		30
475	[Surgery after upfront radiochemotherapy for locally advanced esophageal cancer: To do or not to do?]. <b>2018</b> , 22, 540-545		1
474	Comparing Two Year Survival Rate of Esophageal Cancer Patients with and without Neoadjuvant Chemoradiotherapy Treatment. <b>2018</b> , 10,		
473	Variables Associated to Pathologic Complete Response, Overall Survival and Disease-Free Survival in the Neoadjuvant Setting for Esophageal Cancer: A Retrospective Cohort Analysis. <b>2018</b> , 103, 214-221		2
472	Esophageal Cancer. <b>2018</b> , 403-422		
471	A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival. <b>2018</b> , 127, 80-90		8
470	Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma. <b>2018</b> , 23, 1004-e102		3
469	Radiotherapy and Chemoradiotherapy. <b>2018</b> , 283-297		
468	Stage selection for neoadjuvant radiotherapy in non-cervical esophageal cancer: A propensity score-matched study based on the SEER database. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1111-1120	3.2	1
467	Chemical Therapy. <b>2018</b> , 263-281		
466	GI Cancers-Modulating the Modern Management of Gastrointestinal Malignancies: A Look at Liver Metastases, Rectal Cancer, Esophagogastric Cancer, and Anal Cancer. <b>2018</b> , 101, 749-758		
465	Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation. <b>2018</b> , 366, 410-421		7
464	Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival. <b>2018</b> , 156, 1725-1735		7



463	Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis. <b>2018</b> , 11, 3441-3447		4
462	Esophageal Cancer. <b>2018</b> ,		1
461	Radiation Therapy in Esophageal/Gastroesophageal Cancer. <b>2018</b> , 1-14		
460	Future Directions in Esophageal Cancer. <b>2018</b> , 193-200		
459	The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 2034-2043	3.1	7
458	The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 2409-2417	3.1	6
457	Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluorouracil in patients with squamous cell carcinoma of the esophagus. <b>2018</b> , 13, 139		14
456	Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. <b>2018</b> , 3, e000386		6
455	Timing of esophagectomy after neoadjuvant chemoradiation treatment in squamous cell carcinoma. <i>Surgery</i> , <b>2018</b> , 164, 455-459	3.6	9
454	Gastric Cardiac Cancer. <b>2018</b> ,		2
453	Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival. <i>Ecological Management and Restoration</i> , <b>2019</b> , 32,	3	6
452	Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. <b>2019</b> , 24, 60-67		8
451	Gastrointestinal Cancers: Fine-Tuning the Management of Rectal, Esophageal, and Pancreas Cancers. <b>2019</b> , 105, 1-10		3
450	Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers. <b>2019</b> , 10, 712-722		2
449	Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 4737-4743	3.1	11
448	[Definitive or neo-adjuvant chemoradiation in esophageal carcinoma?]. <b>2019</b> , 23, 716-719		1
447	Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial. <b>2019</b> , 141, 27-32		5
446	Increasing Radiation Dose to the Thoracic Marrow Is Associated With Acute Hematologic Toxicities in Patients Receiving Chemoradiation for Esophageal Cancer. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 147	5.3	2

445	Clinical and translational advances in esophageal squamous cell carcinoma. <b>2019</b> , 144, 95-135			49
444	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <b>2019</b> , 11, 1758835919864850			6
443	Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity. <b>2019</b> , 10, 513-522			2
442	Radiation Therapy for Gastric Cancer. <b>2019</b> , 359-366			
441	Multimodale Therapie bei Adenokarzinomen des Ösophagogastralen Übergangs. <b>2019</b> , 25, 1086-1094			1
440	Treatment in Esophagogastric Junction Cancer: Past, Present and Future. <b>2019</b> , 97, 459-464			
439	Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. <b>2019</b> , 14, 176			5
438	Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma. <b>2019</b> , 121, 1050-1057			4
437	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 101-111	7.5		6
436	Analysis of the National Cancer Database Esophageal Squamous Cell Carcinoma in the United States. <b>2019</b> , 108, 1535-1542			5
435	The prognostic role of angiolymphatic invasion in N0 esophageal carcinoma: a meta-analysis and systematic review. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 3276-3283	2.6		0
434	Performance of the transoral circular stapler for oesophagogastricectomy after induction therapy. <b>2019</b> , 29, 890-896			0
433	. <b>2019</b> , 57, 336-418			10
432	Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. <b>2019</b> , 58, 1358-1365			4
431	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. <b>2019</b> , 5, 1597-1604			35
430	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). <b>2019</b> , 39, 5123-5133			10
429	Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery. <b>2019</b> , 133, 87-92			10
428	Radiation Oncology. <b>2019</b> ,			2

427	Absolute Clinical Radiation Oncology Review. <b>2019</b> ,		2
426	Surgical approach and the impact of epidural analgesia on survival after esophagectomy for cancer: A population-based retrospective cohort study. <b>2019</b> , 14, e0211125		5
425	Surgery for Gastric Cancer. <b>2019</b> ,		1
424	Esophagogastric Junction (EGJ) Carcinoma: An Updated Review. <b>2019</b> , 1-62		
423	Combining the radiomic features and traditional parameters of F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. <b>2019</b> , 33, 657-670		21
422	Quality of life in patients with upper GI malignancies managed by a strategy of chemoradiotherapy alone versus surgery. <b>2019</b> , 30, 33-39		2
421	Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. <b>2019</b> , 10, 391-399		4
420	Stop hedging your bets: reasons for non-adherence to a tri-modality regimen in the treatment of esophageal cancer in a multidisciplinary setting. <b>2019</b> , 10, 387-390		2
419	Monodispersed Copper(II)-Based Nano Metal-Organic Framework as a Biodegradable Drug Carrier with Enhanced Photodynamic Therapy Efficacy. <b>2019</b> , 6, 1900848		89
418	Clinical outcomes and prognostic factors of definitive radiotherapy for esophageal cancer. <b>2019</b> , 66, 99-105		2
417	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
416	Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus. <b>2019</b> , 14, 66		6
415	Timing of Esophagectomy after Neoadjuvant Chemoradiation Therapy Affects the Incidence of Anastomotic Leaks. <b>2019</b> , 52, 1-8		8
414	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <b>2019</b> , 39, 10		199
413	Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma. <b>2019</b> , 39, 1433-1440		16
412	Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. <b>2019</b> , 33, 587-594		4
411	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. <i>Cancers</i> , <b>2019</b> , 11,	6.6	24
410	A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. <b>2019</b> , 4, 63-69		43

409	Optimal management of gastroesophageal junction cancer. <b>2019</b> , 125, 1990-2001	17
408	Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. <b>2019</b> , 99, 479-499	10
407	Managing Squamous Cell Esophageal Cancer. <b>2019</b> , 99, 529-541	22
406	Multidisciplinary Therapy of Esophageal Cancer. <b>2019</b> , 99, 419-437	6
405	Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer. <b>2019</b> , 23, 670-678	8
404	Chemoradiotherapy could improve overall survival of patients with stage IV cutaneous squamous cell carcinoma: analysis of 34 cases. <b>2019</b> , 180, 1557-1558	3
403	Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma. <b>2019</b> , 157, 1682-1693.e1	10
402	Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. <b>2019</b> , 14, 540-546	9
401	Gastrointestinal Cancers. <b>2019</b> , 265-311	
400	Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes?. <b>2019</b> , 107, 903-911	5
399	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. <b>2019</b> , 29, 111-125	2
398	Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction. <i>Ecological Management and Restoration</i> , <b>2019</b> , 32,	3 4
397	Radiation doses in esophageal cancer. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 5688-5690	2.6 1
396	Neoadjuvant radiation therapy for esophageal cancer: is a higher dose better?. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 5631-5634	2.6
395	S3-Leitlinie Magenkarzinom Diagnostik und Therapie der Adenokarzinome des Magens und des Ösophagogastralen Übergangs Langversion 2.0 August 2019. AWMF-Registernummer: 032/009OL. <b>2019</b> , 57, 1517-1632	22
394	Cellular Dissociation Grading Based on the Parameters Tumor Budding and Cell Nest Size in Pretherapeutic Biopsy Specimens Allows for Prognostic Patient Stratification in Esophageal Squamous Cell Carcinoma Independent From Clinical Staging. <b>2019</b> , 43, 618-627	10
393	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. <b>2019</b> , 16, 1-24	200
392	Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. <b>2019</b> , 157, 1264-1272.e6	18

391	Neoadjuvant Chemoradiation Treatment for Resectable Esophago-Gastric Cancer: A Systematic Review and Meta-Analysis. <b>2019</b> , 10, 192-204		9
390	Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era. <b>2019</b> , 5, 318-325		64
389	Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran. <b>2019</b> , 50, 907-912		
388	Preoperative lymph node status on computed tomography influences the survival of pT1b, T2 and T3 esophageal squamous cell carcinoma. <b>2019</b> , 49, 378-386		4
387	A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy. <b>2019</b> , 45, 931-940		15
386	Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma. <b>2019</b> , 83, 581-587		5
385	[Chemoradiation for oesophageal cancer: A critical review of the literature]. <b>2019</b> , 23, 62-72		1
384	Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. <b>2019</b> , 23, 885-894		12
383	Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 200-208	3.1	20
382	Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 861-868	3.1	2
381	Local recurrence of esophageal squamous cell carcinoma after treatment: Comparison of frequentist and Bayesian network meta-analysis. <b>2019</b> , 7, 145-152		1
380	Survival after neoadjuvant approaches to gastroesophageal junction cancer. <b>2020</b> , 23, 175-183		7
379	Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy. <b>2020</b> , 24, 288-298		3
378	Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 500-508	3.1	4
377	Treatment-related toxicity and outcomes in older versus younger patients with esophageal cancer treated with neoadjuvant chemoradiation. <b>2020</b> , 11, 668-674		2
376	Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205). <b>2020</b> , 25, e53-e59		4
375	Cancer of the Esophagus. <b>2020</b> , 1174-1196.e6		
374	Commentary: After neoadjuvant therapy for esophageal cancer, time is on our side. <b>2020</b> , 159, 2567-2568		

373	Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 243-252	3.2	4
372	Esophageal carcinoma: Towards targeted therapies. <b>2020</b> , 43, 195-209		55
371	Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1510-1517	3.1	7
370	Preoperative chemotherapy compared with postoperative adjuvant chemotherapy for squamous cell carcinoma of the thoracic oesophagus with the detection of circulating tumour cells randomized controlled trial. <b>2020</b> , 73, 1-8		8
369	Esophageal Cancer. <b>2020</b> ,		0
368	Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and meta-analysis. <b>2020</b> , 8, 35-43		5
367	Optimal radiation dose in the neoadjuvant management of esophageal cancer. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 4568-4570	2.6	2
366	Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study. <b>2020</b> , 272, 779-785		6
365	Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. <b>2020</b> , 1482, 213-224		13
364	Potential New Cancer Immunotherapy: Anti-CD47-SIRP Antibodies. <b>2020</b> , 13, 9323-9331		8
363	The clinical outcomes of elderly esophageal cancer patients who received definitive chemoradiotherapy. <b>2020</b> , 83, 906-910		1
362	Patterns of Failure After Trimodal Treatment in Esophageal Squamous Cell Carcinoma: Initial Experiences from a High-Risk Endemic Area. <b>2020</b> , 11, 360-366		
361	F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated With Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 599907	5.3	4
360	Imidazole-thiazolidinone inhibits oesophageal cancer cell proliferation via induction of apoptosis and cell cycle arrest at S phase. <b>2020</b> , 19, 51-56		
359	Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). <b>2020</b> , 24, 100422		8
358	The Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Esophageal Cancer Patients: A Systematic Review and Meta-Analysis. <i>World Journal of Surgery</i> , <b>2020</b> , 44, 4161-4174	3.3	4
357	Development of Multiscale Transcriptional Regulatory Network in Esophageal Cancer Based on Integrated Analysis. <b>2020</b> , 2020, 5603958		1
356	Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. <b>2020</b> , 154, 103069		11

355	Robot-Assisted Esophagectomy After Neoadjuvant Chemoradiation-Current Status and Future Prospects. <b>2020</b> , 11, 668-673		
354	Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1431	5.3	4
353	Application of atomic force microscope in diagnosis of single cancer cells. <b>2020</b> , 14, 051501		2
352	External beam radiotherapy with or without californium-252 neutron brachytherapy for treatment of recurrence after definitive chemoradiotherapy. <i>Scientific Reports</i> , <b>2020</b> , 10, 20902	4.9	0
351	Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes. <b>2021</b> , 87, 1145-1154		2
350	Long-Term Outcomes of Induction Chemotherapy Followed by Chemo-Radiotherapy as Intensive Neoadjuvant Protocol in Patients with Esophageal Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
349	Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. <b>2020</b> , 9,		3
348	Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. <b>2020</b> , 3, e2015927		18
347	Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma. <b>2020</b> , 35, 491-497		2
346	Impact of F-FDG-PET/CT on the identification of regional lymph node metastases and delineation of the primary tumor in esophageal squamous cell carcinoma patients. <b>2020</b> , 196, 787-794		1
345	Neoadjuvant and Definitive Radiochemotherapeutic Approaches in Esophageal Cancer: A Retrospective Evaluation of 122 Cases in Daily Clinical Routine. <b>2020</b> , 43, 372-379		2
344	Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 4422-4430	3.1	5
343	Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. <b>2020</b> , 21, 393-402		
342	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2677-2694	2.2	44
341	The emerging role of proton therapy for esophagus cancer. <b>2020</b> , 11, 144-156		5
340	The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 1631-1639	3.6	5
339	Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. <b>2020</b> , 45, 1018-1035		4
338	Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. <b>2020</b> , 85, 711-722		3



337	Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. <b>2020</b> , 24, 88-92		0
336	Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. <b>2020</b> , 18, 59		13
335	The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. <b>2020</b> , 146, 180-186		16
334	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <b>2020</b> , 20, 305-324		
333	Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. <b>2020</b> , 99, e19295		1
332	Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors?. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1496-1507	3.1	5
331	Long-term outcomes of clinical and pathological-staged T3 N3 esophageal cancer. <i>Ecological Management and Restoration</i> , <b>2020</b> , 33,	3	3
330	Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. <b>2020</b> , 147, 1427-1436		6
329	Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. <b>2020</b> , 31, 236-245		19
328	Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer. <b>2020</b> , 9,		3
327	Neoadjuvante Therapie beim Plattenepithelkarzinom des Ösophagus. <b>2020</b> , 26, 323-331		
326	Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer - a cohort study. <b>2020</b> , 59, 859-865		0
325	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. <b>2020</b> , 59, 895-903		6
324	The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation. <i>World Journal of Surgery</i> , <b>2020</b> , 44, 2323-2331	3.3	
323	Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery. <b>2020</b> , 40, 1153-1160		3
322	Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy. <b>2021</b> , 74, 228-233		0
321	Patterns of Recurrence in Locally Advanced Resectable Oesophageal Carcinoma: Retrospective Review from a Tertiary Cancer Centre in South India. <b>2021</b> , 52, 711-718		
320	Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 663-675	3.1	3

319	Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. <b>2021</b> , 22, 93-107	3
318	Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. <b>2021</b> , 99, 49-56	5
317	Multidisciplinary Management of Gastroesophageal Reflux Disease. <b>2021</b> ,	
316	[Surgical treatment of esophageal cancer-Indicators for quality in diagnostics and treatment]. <b>2021</b> , 92, 350-360	2
315	Evaluation and treatment results of trimodality therapy for advanced esophageal squamous cell carcinoma. <b>2021</b> , 18, 181-186	1
314	The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. <b>2021</b> , 10, 1275-1288	1
313	The emerging role of long noncoding RNAs in esophageal carcinoma: from underlying mechanisms to clinical implications. <b>2021</b> , 78, 3403-3422	3
312	Proton beam therapy can achieve lower vertebral bone marrow dose than photon beam therapy during chemoradiation therapy of esophageal cancer. <b>2021</b> , 46, 229-235	0
311	Esophageal Cancers: Leveraging Alterations in Mitochondrial Biology to Improve Patient Outcomes. <b>2021</b> ,	
310	Esophageal Cancer. <b>2021</b> , 1813-1828	
309	Prognostic models for stage I-III esophageal cancer: a comparison between existing calculators. <b>2021</b> , 12, 1963-1972	1
308	Trends in conditional overall survival of esophageal cancer: a population-based study. <b>2021</b> , 9, 102	2
307	Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. <b>2021</b> , 13, e12574	2
306	Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6
305	Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study. <b>2021</b> , 2021, 3834040	
304	Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 626275	5.3 1
303	Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. <i>Cancers</i> , <b>2021</b> , 13,	6.6 3
302	Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. <b>2021</b> , 9, 612451	3

301	Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. <b>2021</b> , 9, 513		1
300	The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 628706	5.3	5
299	Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy. <i>Scientific Reports</i> , <b>2021</b> , 11, 6644	4.9	1
298	Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 614640	5.3	1
297	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. <b>2021</b> , 15, 1195		
296	Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study. <i>Cancer Management and Research</i> , <b>2021</b> , 12, 2113-2120	3.6	2
295	The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. <b>2021</b> , 28, 1354-1365		0
294	SUV reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. <b>2021</b> , 19, 105		2
293	Cytokeratins (CK7 and CK20) Genes Expression Association with in Oral Squamous Cell Carcinoma and Dysplastic Oral Epithelium. <b>2021</b> , 10, 126-134		1
292	Many Birds, One Stone: A Smart Nanodevice for Ratiometric Dual-Spectrum Assay of Intracellular MicroRNA and Multimodal Synergetic Cancer Therapy. <b>2021</b> , 15, 6961-6976		15
291	Metastatic Esophageal Carcinoma: Prognostic Factors and Survival. <b>2021</b> , 1		0
290	Using Genomics Feature Selection Method in Radiomics Pipeline Improves Prognostication Performance in Locally Advanced Esophageal Squamous Cell Carcinoma-A Pilot Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
289	Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 7208-7218	3.1	2
288	Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy. <b>2021</b> , 51, 1496-1505		1
287	The Impact of Radiation to Epicardial Adipose Tissue on Prognosis of Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy and Esophagectomy. <b>2021</b> , 11, 4023		2
286	Application of contrast-enhanced CT radiomics in prediction of early recurrence of locally advanced oesophageal squamous cell carcinoma after trimodal therapy. <b>2021</b> , 21, 38		1
285	Evolving treatment paradigms in esophageal cancer. <b>2021</b> , 9, 903		2
284	Preoperative chemoradiotherapy versus chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction (AEG): systematic review with individual participant data (IPD) network meta-analysis (NMA).		0

283	Machine Learning and Radiomics Applications in Esophageal Cancers Using Non-Invasive Imaging Methods-A Critical Review of Literature. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
282	A narrative review of combining radiation and immunotherapy in gastroesophageal cancers.. <b>2021</b> , 10, 2586-2595		0
281	The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial. <i>Ecological Management and Restoration</i> , <b>2021</b> ,	3	0
280	Identification of differentially expressed proteins in the locoregional recurrent esophageal squamous cell carcinoma by quantitative proteomics. <b>2021</b> , 12, 991-1006		
279	Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer. <b>2021</b> , 40, 4380-4385		3
278	Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. <b>2021</b> , 156, 721-729		17
277	Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. <b>2021</b> , 16, 102		2
276	Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. <i>Scientific Reports</i> , <b>2021</b> , 11, 11626	4.9	1
275	The Prognostic Value of Lymph Node Ratio in Locally Advanced Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 8464-8472	3.1	1
274	Trimodality Approach for Esophageal Malignancies. <b>2021</b> , 101, 453-465		1
273	Salvage Esophagectomy. <b>2021</b> , 101, 467-482		1
272	Socioeconomic factors in timing of esophagectomy and association with outcomes. <i>Journal of Surgical Oncology</i> , <b>2021</b> , 124, 1014-1021	2.8	1
271	Contrast-enhanced CT radiomics features to predict recurrence of locally advanced oesophageal squamous cell cancer within 2 years after trimodal therapy: A case-control study. <b>2021</b> , 100, e26557		1
270	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <b>2021</b> , 41, 747-795		36
269	Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?. <b>2021</b> , 12, 557-564		2
268	CA19-9-producing esophageal adenocarcinoma originating from the esophageal cardia of the mid-thoracic esophagus: a case report. <b>2021</b> , 7, 166		1
267	Relationship between alcohol consumption and the risks of liver cancer, esophageal cancer, and gastric cancer in China: Meta-analysis based on case-control studies. <b>2021</b> , 100, e26982		3
266	Primary Chemoradiotherapy for Older Patients With Esophageal Cancer. <b>2021</b> , 7, 1451-1452		0

265	Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. <b>2021</b> , 1		0
264	Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines. <b>2021</b> , 11, 429-433		0
263	Oligometastatic Adenocarcinoma of the Esophagus: Current Understanding, Diagnosis, and Therapeutic Strategies. <i>Cancers</i> , <b>2021</b> , 13,	6.6	0
262	Combination of 35-Gene Mutation Profile and Radiotherapy Dosimetry Predicts the Therapeutic Outcome of Definitive Chemoradiation in Patients With Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 729418	5.3	
261	Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2803-2815	2.2	7
260	Predictive Model for Overall Survival and Cancer-Specific Survival in Patients with Esophageal Adenocarcinoma. <b>2021</b> , 2021, 4138575		0
259	Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study.. <b>2021</b> , 10, 151-154		
258	Chemoradiotherapy Is Superior to Radiotherapy Alone in Esophageal Cancer Patients Older Than 65 Years: A Propensity Score-Matched Analysis of the SEER Database. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 736448	5.3	2
257	Anastomotic leakage and postoperative mortality in patients after esophageal cancer resection. <b>2021</b> , 49, 3000605211045540		1
256	Combined Therapy of Locally Advanced Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	
255	Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review. <b>2021</b> , 111, 405-416		6
254	In Regard to Ying Li et al. <b>2021</b> , 111, 581		1
253	Nanocarriers for the Diagnosis and Treatment of Cancer. <b>2021</b> , 223-252		
252	Approach to the Patient with Gas and Bloating. 723-734		1
251	Oesophagus. 280-296		1
250	Esophageal Cancer. <b>2012</b> , 571-579		1
249	Induction Therapy for Resectable Esophageal Cancer. <b>2011</b> , 203-212		1
248	Multimodality therapy for adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. <b>2010</b> , 182, 155-66		2

247	Surgical Approaches to Remove the Esophagus. <b>2019</b> , 405-414	1
246	Interaction of Chemotherapy and Radiation. <b>2012</b> , 65-82	9
245	Gastric/GE Junction Cancer. <b>2012</b> , 903-933	2
244	Treatment in esophagogastric junction cancer: Past, present and future. <b>2019</b> , 97, 459-464	2
243	Esophagus and Gastrointestinal Junction Tumors. <b>2020</b> , 100, 507-521	6
242	The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. <b>2020</b> , 275,	5
241	Recent advances in preoperative management of esophageal adenocarcinoma. <b>2017</b> , 6, 501	1
240	Recent advances in treating oesophageal cancer. <b>2020</b> , 9,	7
239	Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study. <b>2017</b> , 12, e0177133	12
238	Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer. <b>2015</b> , 1, 866-877	22
237	Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery. <b>2017</b> , 8, 3542-3552	6
236	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. <b>2017</b> , 8, 24372-24379	6
235	Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials. <b>2017</b> , 8, 20410-20417	21
234	Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. <b>2017</b> , 8, 36339-36353	9
233	The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. <b>2017</b> , 8, 96190-96202	9
232	Prognostic value of resected lymph nodes numbers for Siewert II gastroesophageal junction cancer. <b>2018</b> , 9, 2797-2809	5
231	Emerging therapeutic targets in esophageal adenocarcinoma. <b>2016</b> , 7, 48644-48655	10
230	Surveillance or resection after chemoradiation in esophageal cancer. <b>2018</b> , 6, 82	5

229	Surgery within multimodal therapy concepts for esophageal squamous cell carcinoma (ESCC): the MRI approach and review of the literature. <b>2009</b> , 54, 158-69	17
228	The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells. <b>2014</b> , 21, 281-6	4
227	Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. <b>2009</b> , 15, 4962-8	64
226	Neoadjuvant treatment of esophageal cancer. <b>2010</b> , 16, 3793-803	46
225	Transhiatal versus transthoracic esophagectomy for esophageal cancer. <b>2010</b> , 16, 3804-10	60
224	Multimodality approach for locally advanced esophageal cancer. <b>2012</b> , 18, 5679-87	19
223	Multidisciplinary approach for patients with esophageal cancer. <b>2012</b> , 18, 6737-46	18
222	Treatment of esophagogastric junction carcinoma: an unsolved debate. <b>2015</b> , 21, 4427-31	3
221	Preoperative therapy in locally advanced esophageal cancer. <b>2016</b> , 22, 8750-8759	10
220	oil emulsion improves the effect of radiotherapy on esophageal cancer cells by inhibiting cyclin D1-CDK4/6 axis. <b>2019</b> , 25, 2463-2472	9
219	Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. <b>2015</b> , 33, 12-20	3
218	Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy. <b>2017</b> , 32, 443-451	3
217	A Case of Pathologic Complete Response with Neoadjuvant Biweekly-DCF Therapy and following Laparoscopic Transhiatal Extended Total Gastrectomy for Advanced Esophagogastric Junction Adenocarcinoma. <b>2019</b> , 80, 707-713	1
216	Process Parameters Optimisation of Mannanase Production from <i>Aspergillus niger</i> FTCC 5003 Using Palm Kernel Cake as Carbon Source. <b>2008</b> , 3, 297-307	4
215	Esophageal cancer: staging system and guidelines for staging and treatment. <i>Journal of Thoracic Disease</i> , <b>2014</b> , 6 Suppl 3, S289-97	2.6 71
214	Radiation therapy in the postoperative management of esophageal cancer. <b>2010</b> , 1, 102-11	16
213	Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma. <b>2013</b> , 4, 137-43	11
212	Current strategies in chemoradiation for esophageal cancer. <b>2014</b> , 5, 156-65	35



211	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. <b>2015</b> , 6, 45-52	15
210	Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. <b>2015</b> , 6, 39-44	5
209	Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. <b>2016</b> , 7, 173-80	3
208	Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre. <b>2016</b> , 22, 288-94	3
207	A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma. <b>2015</b> , 20, 751-6	7
206	Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature. <b>2017</b> , 54, 646-651	7
205	Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: A prospective randomized study. <b>2018</b> , 7, 27-30	10
204	Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy. <b>2017</b> , 49, 669-677	30
203	Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. <b>2019</b> , 11, 518-526	8
202	Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. <b>2020</b> , 12, 37-53	18
201	Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. <b>2012</b> , 4, 103-8	14
200	Neoadjuvant treatment for esophageal squamous cell carcinoma. <b>2014</b> , 6, 121-8	46
199	Operable gastro-oesophageal junctional adenocarcinoma: Where to next?. <b>2014</b> , 6, 145-55	2
198	Esophageal cancer management controversies: Radiation oncology point of view. <b>2014</b> , 6, 263-74	13
197	Role of radiotherapy in the pre-operative management of carcinoma of the esophagus. <b>2015</b> , 7, 1-5	9
196	Intensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esophageal adenocarcinoma. <b>2016</b> , 8, 474-80	5
195	Neoadjuvant therapy for gastroesophageal adenocarcinoma. <b>2016</b> , 7, 284-92	7
194	The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. <b>2012</b> , 31, 399-408	8

193	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <b>2019</b> , 17, 855-883		267
192	Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy. <b>2012</b> , 13, 199-203		20
191	Simultaneous Comparison of Efficacy and Adverse Events of Interventions for Patients with Esophageal Cancer: Protocol for a Systematic Review and Bayesian Network Meta-analysis. <b>2016</b> , 17, 867-72		5
190	Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review. <b>2014</b> , 11, 191-201		20
189	Epidemiology and Survival of Esophageal Cancer Patients in an American Cohort. <b>2018</b> , 10, e2507		15
188	Paclitaxel and Carboplatin Cisplatin and 5-Fluorouracil in Concurrent Chemoradiotherapy in Patients With Esophageal Cancer. <b>2021</b> , 35, 3391-3399		0
187	Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India. <b>2021</b> , 33, 35		
186	Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
185	A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. <i>Cancer Management and Research</i> , <b>2021</b> , 13, 7773-7782 <sup>O</sup>		
184	Adjuvant chemotherapy for node-positive esophageal squamous cell carcinoma improves survival. <b>2021</b> ,		0
183	PET Imaging and Rate of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 1	3.1	2
182	The Influence of Different Treatment Strategies on the Long-Term Prognosis of T1 Stage Esophageal Cancer Patients. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 700088	5.3	0
181	[Preoperative chemoradiotherapy in locally advanced esophageal cancer]. <b>2009</b> , 56, 83-9		1
180	????????????????????(intensity modulated radiation therapy:IMRT)?????????1?. <b>2009</b> , 34, 813-819		
179	Carcinoma of the Esophagus. <b>2010</b> , 503-510		
178	Neoadjuvant and Adjuvant Therapy for Esophageal Cancer. <b>2010</b> , 617-622		
177	Esophageal Cancer. <b>2010</b> , 315-330		
176	Cancer of the Esophagus. <b>2010</b> , 772-787		0

175 Esophageal Cancer. **2011**, 67-100

174 Combined Modality Therapy in Cancer Management. **2011**, 483-517

173 Neoadjuvant and Adjuvant Therapy for Esophageal Carcinoma. **2011**, 53-56

172 Esophageal Surgery for Malignant Disease in the Elderly. **2011**, 535-551

171 Multimodal Treatment: Early and Long-term Results and Recurrences. **2012**, 113-128

170 Overview. **2012**, 891-902

169 Neoadjuvant Treatment. **2012**, 131-138

168 Cancer of the Esophagus. **2012**, 839-858

167 Overview. **2012**, 783-793

166 Surgery for Cancer of the Esophagus and Gastroesophageal Junction. 637-668

165 Will disease heterogeneity help define treatment paradigms for gastroesophageal adenocarcinoma? A global perspective. **2012**, 256-9

164 Surrogate Markers: The Role of Positron Emission Tomography Scanning. **2013**, 275-296

163 Ösophaguskarzinom. **2013**, 197-201

162 Multimodality Treatment for Potentially Resectable Esophageal Cancer. **2013**, 451-461

161 Esophageal Cancer. **2013**, 1-19

160 E. **2013**, 343-392

159 Endoscopy in Esophageal Cancer: An Oncologist's Perspective. 51-55

158 The Rationale and Evidence for Radiotherapy in the Management of Gastroesophageal Junction Tumors. **2013**, e151-e154

o

157 Distal esophageal tumors. **2013**, 196-210

156 Cancer of the Esophagus. **2014**, 1207-1239.e7

155 Cancer of the Stomach and Gastroesophageal Junction. **2014**, 1240-1270.e7

1

154 Esophageal Cancer: Neoadjuvant and Adjuvant Therapy. **2014**, 227-240

153 Preoperative Chemo Versus Chemoradiotherapy for Regionally Advanced Esophageal Adenocarcinoma. **2014**, 287-299

152 Salvage Esophagectomy for Persistent or Recurrent Disease After Definitive Chemoradiotherapy. **2014**, 351-364

151 Esophageal Cancer. **2015**, 171-193

150 Thoracic Esophageal Cancer. **2015**, 301-314

149 The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. **2015**, 203-220

148 The Multidisciplinary Management of Early-Stage Thoracic Esophageal Cancer. **2015**, 187-201

147 Oesophageal cancer and dysphagia. **2015**, 77-88

146 Esophageal Squamous Cell Carcinomas and Other Neoplasms. 975-988

145 Multimodality treatment for locally advanced esophageal cancers. **2015**, 4, 99-107

144 Esophageal Cancer. **2016**, 225-229

143 Esophageal Cancer. **2016**, 297-324

142 The effect of time interval on esophagectomy after neoadjuvant treatment. **2016**, 4, 117

3

141 Dysphagia in Gastrointestinal Cancer Patients. **2017**, 7, 1-7

1

140 Chemoradiation in Esophagogastric Junction Cancer. **2017**, 149-161

139 Recurrence: Treatment or Just Palliation?. **2017**, 225-235

138 Gastrointestinal Brachytherapy: Esophageal Cancer. **2017**, 273-288

137 Esophageal Cancer: Background and Clinical Evidence. **2017**, 23-38

136 Neoadjuvant Treatment of Esophageal and Gastro-Esophageal Cancer. **2017**, 33-42

135 Oesophagus. 280-296

134 First Clinical Report on Comparative Treatment and Survival Outcomes in Second Cancers after Primary Head and Neck Cancer: A Population-Based Study. **2017**, 9, e1284

1

133 Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?. *Journal of Thoracic Disease*, **2017**, 9, 3594-3597

2.6

132 Esophageal Cancer in the Elderly. **2018**, 1-11

131 Neoadjuvant and Adjuvant Therapy. **2018**, 55-63

130 Ösophaguskarzinom. **2018**, 177-214

129 Esophageal Cancer. **2019**, 271-301

128 Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. **2019**, e.1-e.39

127 Dosimetric Comparison between Three Dimensional Conformal Radiation Therapy (3DCRT) & Intensity Modulated Radiation Therapy (IMRT) in Mid-Lower Oesophageal Carcinoma. **2019**, 08, 121-129

1

126 Advances in Radiation Therapy for Gastrointestinal Cancers. **2019**, 421-443

125 Esophageal and Gastroesophageal Junction Tumors. **2019**, 55-71

124 Gastrointestinal System Cancers. **2019**, 197-268

123 Multimodality Therapy in the Management of Locally Advanced Esophageal Cancer. **2019**, 391-404

122 New Insights in the Pathogenesis of Cisplatin-Induced Nephrotoxicity. **2019**,

121	The Multidisciplinary Management of Early-Stage Thoracic Esophageal Cancer. <b>2020</b> , 237-250		
120	Principles of Radiation Therapy. <b>2020</b> , 199-220		
119	The Multidisciplinary Management of Early-Stage Cervical Esophageal Cancer. <b>2020</b> , 221-236		
118	The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. <b>2020</b> , 251-273		
117	Preoperative Chemoradiation in Locally-Advanced Resectable Carcinoma of the Esophagus in a Single Rural Cancer Hospital in Western India. <b>2020</b> , 9, 158-162		
116	A multinational review: Oesophageal cancer in low to middle-income countries. <b>2020</b> , 20, 42		4
115	Risk prediction of occult lymph node metastasis in patients with clinical T1 through T2 N0 esophageal squamous cell carcinoma. <b>2021</b> ,		1
114	Radiation Therapy for Esophageal Squamous Cell Carcinoma. <b>2020</b> , 283-307		
113	Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. <b>2020</b> , 8, 411-424		1
112	Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus. <b>2021</b> , 4, e1332		1
111	Surgery following neoadjuvant chemoradiation therapy in clinical N3 esophageal cancer results in improved survival: a propensity-matched analysis. <i>Ecological Management and Restoration</i> , <b>2021</b> , 34,	3	0
110	Salvage Esophagectomy for Persistent or Recurrent Disease After Chemoradiation. <b>2020</b> , 387-399		
109	Esophageal Cancer. <b>2020</b> , 1-16		
108	Does Induction Therapy for T2N0 Esophageal Adenocarcinoma Patients Improve Survival?. <b>2020</b> , 305-315		
107	Esophageal Cancer in the Elderly. <b>2020</b> , 957-966		
106	Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 748331	5.3	0
105	mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma. <b>2021</b> , 1		0
104	Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis. <b>2021</b> , 42, 101183		2

103	Long term follow-up of a large patient population with stage 2 and 3 esophageal cancer. <b>2020</b> , 110-115		
102	Surgical Treatment of Esophageal Adenocarcinoma. <b>2021</b> , 151-173		
101	Crossroads in the combined-modality management of gastroesophageal junction carcinomas. <b>2008</b> , 2, 235-43		4
100	In pursuit of progress: multimodality strategies will form the cornerstone of cure for esophageal cancer. <b>2009</b> , 3, 74-6		
99	Chemoradiotherapy for esophageal cancer. <b>2009</b> , 3, 57-65		11
98	Localized gastric or gastroesophageal cancer - chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse. <b>2009</b> , 3, S26-32		2
97	Epidemiology and biology of esophageal cancer. <b>2009</b> , 3, S2-5		31
96	Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers. <b>2009</b> , 3, S6-S10		5
95	Accomplishments in 2008 in the management of esophageal cancer. <b>2009</b> , 3, S53-7		3
94	Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. <b>2011</b> , 4, 45-52		13
93	Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer. <b>2011</b> , 4, 84-9		2
92	Clinical T2N0M0 carcinoma of thoracic esophagus. <i>Journal of Thoracic Disease</i> , <b>2010</b> , 2, 36-42	2.6	5
91	Helical tomotherapy for radiochemotherapy in esophageal cancer: a preferred plan?. <i>Journal of Thoracic Disease</i> , <b>2009</b> , 1, 3-4	2.6	2
90	Esophageal cancer: Is preoperative chemoradiation the new standard?. <b>2010</b> , 1, 68-9		5
89	Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. <b>2012</b> , 5, 85-92		4
88	Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents. <b>2011</b> , 10, 28-42		7
87	High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. <b>2013</b> , 6, 2497-505		29
86	Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer. <b>2014</b> , 5, 86-91		8



85	The role of induction therapy. <i>Journal of Thoracic Disease</i> , <b>2014</b> , 6 Suppl 3, S309-13	2.6	2
84	High level of microtubule-associated protein light chain 3 predicts poor prognosis in resectable esophageal squamous cell carcinoma. <b>2014</b> , 7, 4213-21		7
83	How well does pathologic stage predict survival for esophageal adenocarcinoma after neoadjuvant therapy?. <i>Journal of Thoracic Disease</i> , <b>2015</b> , 7, 734-9	2.6	3
82	Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. <b>2016</b> , 7, 166-72		0
81	Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of esophageal squamous cancers. <b>2016</b> , 6, 2054-2063		7
80	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?. <b>2020</b> ,		2
79	Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy. <b>2021</b> , 21, 1192		0
78	Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 756440	5.3	0
77	PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. <b>2021</b> ,		2
76	PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.. <b>2021</b> , 13, 17588359211065153		0
75	Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: A systematic review and meta-analysis.. <b>2022</b> , 97, 106206		0
74	Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy.. <b>2021</b> , 13, 200231		0
73	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma. <b>2020</b> , Publish Ahead of Print,		3
72	ASO Author Reflections: Opting for a Cost-Effective Treatment Allocation in Patients with Esophageal Cancer.. <i>Annals of Surgical Oncology</i> , <b>2022</b> , 1	3.1	
71	Routine Radiologic Assessment for Anastomotic Leak Is Not Necessary in Asymptomatic Patients After Esophagectomy for Esophageal Cancer.. <b>2022</b> , 26, 279		
70	Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
69	Molecular mechanisms associated with chemoresistance in esophageal cancer.. <b>2022</b> , 79, 116		1
68	Esophageal cancer: emerging therapeutics.. <b>2022</b> ,		8

67	HPRT1 Promotes Chemoresistance in Oral Squamous Cell Carcinoma via Activating MMP1/PI3K/Akt Signaling Pathway.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
66	Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.. <i>Thoracic Cancer</i> , <b>2022</b> ,	3.2	2
65	Effect of prior cancer history on survival of patients with esophageal carcinoma: a propensity score matching, population-based study.. <i>Journal of Thoracic Disease</i> , <b>2022</b> , 14, 979-994	2.6	
64	Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
63	Esophageal squamous cell carcinomas and other neoplasms. <b>2022</b> , 894-908		
62	Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.. <i>Current Oncology Reports</i> , <b>2022</b> , 1	6.3	1
61	Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1	4.9	1
60	Neoadjuvant Therapy for Locally Advanced Esophageal Cancers.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 734581	5.3	0
59	Neoadjuvant chemoradiotherapy, chemotherapy, and radiotherapy do not significantly increase the incidence of anastomotic leakage after esophageal cancer surgery: a meta-analysis.. <i>Ecological Management and Restoration</i> , <b>2021</b> ,	3	
58	Sociodemographic and Facility-Related Disparities in the Delivery of Guideline-Concordant Therapy Among Patients With Esophageal Adenocarcinoma.. <i>JCO Oncology Practice</i> , <b>2022</b> , OP2100912	2.3	
57	DataSheet_1.docx. <b>2020</b> ,		
56	Current and future strategies for radiation therapy in gastric cancer.. <i>Journal of Surgical Oncology</i> , <b>2022</b> , 125, 1161-1175	2.8	0
55	The Radiation Dose to the Left Supraclavicular Fossa is Critical for Anastomotic Leak Following Esophagectomy - A Dosimetric Outcome Analysis.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 1603-1613	3.6	
54	Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma.. <i>World Journal of Surgery</i> , <b>2022</b> , 1	3.3	0
53	Predictive value of clinical and F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma.. <i>Scientific Reports</i> , <b>2022</b> , 12, 7148	4.9	
52	Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy.. <i>Surgery</i> , <b>2022</b> ,	3.6	
51	Salvage Surgery for Recurrent Disease after Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.. <i>Annals of Surgical Oncology</i> , <b>2022</b> ,	3.1	
50	Stomach (Gastric) Cancer. <b>2022</b> , 371-393		

49	The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial. <i>Thoracic Cancer</i> ,	3.2	o
48	Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. <i>European Journal of Cancer</i> , <b>2022</b> , 170, 119-130	7.5	o
47	Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study. <i>Cancers</i> , <b>2022</b> , 14, 2610	6.6	o
46	Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?. <i>Cancers</i> , <b>2022</b> , 14, 3026	6.6	o
45	Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?. <i>Clinical Oncology</i> , <b>2022</b> ,	2.8	o
44	Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy. <i>Frontiers in Oncology</i> , 12,	5.3	
43	Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis. <i>Thoracic Cancer</i> ,	3.2	o
42	COQ10B Knockdown Modulates Cell Proliferation, Invasion, Migration, and Apoptosis in Esophageal Squamous Cell Carcinoma. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2022</b> , 2022, 1-9	2.3	
41	To compare neoadjuvant concurrent chemo-radiotherapy followed by surgery and neoadjuvant chemotherapy followed by surgery in carcinoma esophagus patients: A single institutional study in the Indian population. <b>2022</b> , 0		
40	Endoscopic Treatment for Disease Persistence/Recurrence after Definitive Chemoradiotherapy for Esophageal Cancer. <b>2022</b> , 2, 132-142		
39	New Approaches to Neoadjuvant Treatment for Locally Advanced Esophageal Cancer. <b>2022</b> , 2, 143-153		
38	Nomogram constructed by immunological and inflammatory indicators for predicting prognosis of patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy plus surgery. 12,		
37	Adjuvant Chemotherapy for Pathological Node-Positive Disease in Squamous Cell Carcinoma of the Esophagus after Neoadjuvant Chemoradiotherapy Plus Surgery. <b>2022</b> , 12, 1252		
36	Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis. <b>2022</b> , 17, e0271242		
35	Patterns of care amongst older adults diagnosed with locally advanced esophageal cancer: A cohort study. <b>2022</b> ,		
34	Escalade de dose dans les cancers de l'œophage: revue de la littérature. <b>2022</b> ,		
33	Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis. 12,		o
32	Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis. <b>2022</b> ,		

- 31 Prognostic Effect of the Dose of Radiation Therapy and Extent of Lymphadenectomy in Patients Receiving Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma. **2022**, 11, 5059 ○
- 30 Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node-positive esophageal squamous cell carcinoma: Is oral chemotherapy promising?. ○
- 29 Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis. ○
- 28 No survival benefit could be obtained from adjuvant radiotherapy in esophageal cancer treated with neoadjuvant chemotherapy followed by surgery: A SEER-based analysis. 12, ○
- 27 Esophageal Cancer: Whether and What Before or After Surgery?. ○
- 26 Radiotherapy target volumes in esophageal cancer: The twisting kaleidoscope. **2022**, 0 ○
- 25 Signaling pathways and therapeutic interventions in gastric cancer. **2022**, 7, ○
- 24 High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated Radiation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial. **2022**, 23, ○
- 23 Neoplasms of the Esophagus. 1-20 ○
- 22 Comments on [Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis] ○
- 21 Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma. ○
- 20 Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer. ○
- 19 Neoadjuvant Therapy in Esophageal Cancer. **2022**, 32, 447-456 ○
- 18 Adjuvant Therapies for Esophageal Cancer. **2022**, 32, 457-465 ○
- 17 Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma. **2022**, 10, ○
- 16 Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses. ○
- 15 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters can Predict Long-Term Outcome Following Trimodality Treatment for Oesophageal Cancer. **2022**, ○
- 14 Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives. ○

- 13 Esophageal cancer. **2022**, 237-270 ○
- 12 CT-based radiomics for predicting radio-chemotherapy response and overall survival in nonsurgical esophageal carcinoma. ○
- 11 Tri-modality therapy in advanced esophageal carcinoma: long-term results and insights from a developing world, institutional cohort. ○
- 10 Impact of Delaying Surgery After Chemoradiation on Outcomes for Locally Advanced Esophageal Squamous Cell Carcinoma. ○
- 9 Incidence and Management of Esophageal Cancer Recurrence to Regional Lymph Nodes After Curative Esophagectomy. ○
- 8 Waiting to Operate. Publish Ahead of Print, ○
- 7 Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer. 13, ○
- 6 Neoadjuvant Strategies for Esophageal Cancer. **2023**, 33, 197-208 ○
- 5 Neoadjuvante Radiochemotherapie bei Adenokarzinomen des Ösophagogastralen Übergangs. ○
- 4 Diffusely infiltrative squamous cell carcinoma of the esophagus resembling scirrhous gastric cancer: a case report. **2023**, 85, 266-270 ○
- 3 Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy. ○
- 2 Improving outcomes in patients with oesophageal cancer. ○
- 1 Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients. 15, 621-633 ○